var title_f12_46_13024="Valved T-adaptor for nebulization during mechanical ventilation";
var content_f12_46_13024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Valved T-adaptor for nebulization during mechanical ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The valved T-adaptor can be used as a permanent part of the ventilator tubing. A spring-loaded valve opens and closes the circuit during nebulizer insertion and removal for addition of medication.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo reproduced with the permission of CareFusion Corporation. Copyright &copy; 2012. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13024=[""].join("\n");
var outline_f12_46_13024=null;
var title_f12_46_13025="The 2010 Prohibited List";
var content_f12_46_13025=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The World Anti-Doping Agency 2010 Prohibited List",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Substances and methods prohibited at all times (in- and out-of-competition)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Androgens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Exogenous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1-androstendiol (5&alpha;-androst-1-ene-3&beta;, 17&beta;-diol )",
"       </td>",
"       <td>",
"        Ethylestrenol (19-nor-17&alpha;-pregn-4-en-17-ol)",
"       </td>",
"       <td>",
"        Methyldienolone (17&beta;-hydroxy-17&alpha;-methylestra-4,9-dien-3-one)",
"       </td>",
"       <td>",
"        Oxandrolone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1-androstendione (5&alpha;-androst-1-ene-3,17-dione)",
"       </td>",
"       <td>",
"        Fluoxymesterone",
"       </td>",
"       <td>",
"        Methyl-1-testosterone (17&beta;-hydroxy-17&alpha;-methyl-5&alpha;-androst-1-en-3-one)",
"       </td>",
"       <td>",
"        Oxymesterone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Bolandiol (19-norandrostenediol)",
"       </td>",
"       <td>",
"        Formebolone",
"       </td>",
"       <td>",
"        Methylnortestosterone (17&beta;-hydroxy-17&alpha;-methylestr-4-en-3-one)",
"       </td>",
"       <td>",
"        Oxymetholone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Bolasterone",
"       </td>",
"       <td>",
"        Furazabol (17&beta;-hydroxy-17&alpha;-methyl-5&alpha;-androstano[2,3-c]-furazan)",
"       </td>",
"       <td>",
"        Methyltestosterone",
"       </td>",
"       <td>",
"        Prostanozol (17&beta;-hydroxy-5&alpha;-androstano[3,2-c] pyrazole)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Boldenone",
"       </td>",
"       <td>",
"        Gestrinone",
"       </td>",
"       <td>",
"        Metribolone (methyltrienolone, 17&beta;-hydroxy-17&alpha;-methylestra-4,9,11-trien-3-one)",
"       </td>",
"       <td>",
"        Quinbolone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Boldione (androsta-1,4-diene-3,17-dione)",
"       </td>",
"       <td>",
"        4-hydroxytestosterone (4,17&beta;-dihydroxyandrost-4-en-3-one)",
"       </td>",
"       <td>",
"        Mibolerone",
"       </td>",
"       <td>",
"        Stanozolol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Calusterone",
"       </td>",
"       <td>",
"        Mestanolone",
"       </td>",
"       <td>",
"        Nandrolone",
"       </td>",
"       <td>",
"        Stenbolone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Clostebol",
"       </td>",
"       <td>",
"        Mesterolone",
"       </td>",
"       <td>",
"        19-norandrostenedione (estr-4-ene-3,17-dione)",
"       </td>",
"       <td>",
"        1-testosterone (17&beta;-hydroxy-5&alpha;-androst-1-en-3-one)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Danazol (17&alpha;-ethynyl-17&beta;-hydroxyandrost-4-eno[2,3-d]isoxazole)",
"       </td>",
"       <td>",
"        Metenolone",
"       </td>",
"       <td>",
"        Norboletone",
"       </td>",
"       <td>",
"        Tetrahydrogestrinone (18a-homo-pregna-4,9,11-trien-17&beta;-ol-3-one)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Dehydrochlormethyltestosterone (4-chloro-17&beta;-hydroxy-17&alpha;-methylandrosta-1,4-dien-3-one)",
"       </td>",
"       <td>",
"        Methandienone (17&beta;-hydroxy-17&alpha;-methylandrosta-1,4-dien-3-one)",
"       </td>",
"       <td>",
"        Norclostebol",
"       </td>",
"       <td>",
"        Trenbolone and other substances with a similar chemical structure or similar biological effect(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Desoxymethyltestosterone (17&alpha;-methyl-5&alpha;-androst-2-en-17&beta;-ol)",
"       </td>",
"       <td>",
"        Methandriol",
"       </td>",
"       <td>",
"        Norethandrolone",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Drostanolone",
"       </td>",
"       <td>",
"        Methasterone (2&alpha;, 17&alpha;-dimethyl-5&alpha;-androstane-3-one-17&beta;-ol)",
"       </td>",
"       <td>",
"        Oxabolone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Endogenous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Androstenediol (androst-5-ene-3&beta;, 17&beta;-diol)",
"       </td>",
"       <td>",
"        Testosterone and the following metabolites and isomers:",
"       </td>",
"       <td>",
"        Androst-4-ene-3&beta;,17&alpha;-diol",
"       </td>",
"       <td>",
"        Epitestosterone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Androstenedione (androst-4-ene-3,17-dione)",
"       </td>",
"       <td>",
"        5&alpha;-androstane-3&alpha;, 17&alpha;-diol",
"       </td>",
"       <td>",
"        Androst-5-ene-3&alpha;,17&alpha;-diol",
"       </td>",
"       <td>",
"        3&alpha;-hydroxy-5&alpha;-androstan-17-one",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Dihydrotestosterone (17&beta;-hydroxy-5&alpha;-androstan-3-one)",
"       </td>",
"       <td>",
"        5&alpha;-androstane-3&alpha;,17&beta;-diol",
"       </td>",
"       <td>",
"        Androst-5-ene-3&alpha;,17&beta;-diol",
"       </td>",
"       <td>",
"        3&beta;-hydroxy-5&alpha;-androstan-17-one",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Prasterone (dehydroepiandrosterone, DHEA)",
"       </td>",
"       <td>",
"        5&alpha;-androstane-3&beta;,17&alpha;-diol",
"       </td>",
"       <td>",
"        Androst-5-ene-3&beta;,17&alpha;-diol",
"       </td>",
"       <td>",
"        19-norandrosterone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        5&alpha;-androstane-3&beta;,17&beta;-diol",
"       </td>",
"       <td>",
"        4-androstenediol (androst-4-ene-3&beta;,17&beta;-diol)",
"       </td>",
"       <td>",
"        19-noretiocholanolone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Androst-4-ene-3&alpha;,17&alpha;-diol",
"       </td>",
"       <td>",
"        5-androstenedione (androst-5-ene-3,17-dione)",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Androst-4-ene-3&alpha;,17&beta;-diol",
"       </td>",
"       <td>",
"        Epi-dihydrotestosterone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Clenbuterol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Selective androgen receptor modulators (SARMs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Tibolone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Zeranol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Zilpaterol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Peptide hormones, growth factors, and related substances (and their releasing factors)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Erythropoiesis-stimulating agents [eg, erythropoietin (EPO), darbepoetin (dEPO), methoxy polyethylene glycol-epoetin beta, hematide]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Chorionic gonadotrophin (CG) and luteinizing hormone (LH) in males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Insulins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Corticotrophins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Growth hormone (GH), insulin-like growth factor-1 (IGF-1), mechano growth factors (MGFs), platelet-derived growth factor (PDGF), fibroblast growth factors (FGFS), vascular-endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) as well as any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fiber type switching",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Platelet-derived preparations (eg, platelet rich plasma, \"bloodspinning\") administered by intramuscular route. Other routes of administration require a declaration of use in accordance with the International Standard for Therapeutic Use Exemptions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Other substances with similar chemical structure or similar biological effect(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Beta-2 agonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        <p>",
"         All beta-2 agonists (including both optical isomers where relevant) are prohibited except salbutamol (maximum 1600 micrograms over 24 hours) and salmeterol by inhalation which require a declaration of use in accordance with the International Standard for Therapeutic Use Exemptions.",
"        </p>",
"        <p>",
"         The presence of salbutamol in urine in excess of 1000 ng/ml is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding unless the athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of a therapeutic dose (maximum 1600 micrograms over 24 hours) of inhaled salbutamol.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Hormone antagonists and modulators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Aromatase inhibitors including, but not limited to: aminoglutethimide, anastrozole, androsta-1,4,6-triene-3, 17-dione(androstatrienedione), 4-androstene-3,6,17 trione (6-oxo), exemestane, formestane, letrozole, testolactone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Agents modifying myostatin function(s) including but not limited to myostatin inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Diuretics and other masking agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Masking agents include diuretics, probenecid, plasma expanders (eg, glycerol, intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol), and other substances with similar biological effect(s).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Diuretics include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Acetazolamide",
"       </td>",
"       <td>",
"        Canrenone",
"       </td>",
"       <td>",
"        Furosemide",
"       </td>",
"       <td>",
"        Spironolactone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Amiloride",
"       </td>",
"       <td>",
"        Chlorthalidone",
"       </td>",
"       <td>",
"        Indapamide",
"       </td>",
"       <td>",
"        Thiazides (eg, bendroflumethiazide, chlorothiazide, hydrochlorothiazide)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Bumetanide",
"       </td>",
"       <td>",
"        Etacrynic acid",
"       </td>",
"       <td>",
"        Metolazone",
"       </td>",
"       <td>",
"        Triamterene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Other substances with a similar chemical structure or similar biological effect(s) (except drosperinone, pamabrom and topical dorzolamide and brinzolamide, which are not prohibited)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        A Therapeutic Use Exemption for diuretics and masking agents is not valid if an athlete's urine contains such substance(s) in association with threshold or subthreshold levels of an exogenous prohibited substance(s).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Enhancement of oxygen transfer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Blood doping, including the use of autologous, homologous, or heterologous blood or red blood cell products of any origin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Artificially enhancing the uptake, transport or delivery of oxygen, including but not limited to perfluorochemicals, efaproxiral (RSR13) and modified hemoglobin products (eg, hemoglobin-based blood substitutes, microencapsulated hemoglobin products), excluding supplemental oxygen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Chemical and physical manipulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Tampering, or attempting to tamper, in order to alter the integrity and validity of samples collected during doping controls, including but not limited to: catheterization, urine substitution and/or adulteration (eg, proteases)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Intravenous infusions, except for those legitimately received in the course of hospital admissions or clinical investigations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Gene doping",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        The following, with the potential to enhance athletic performance, are prohibited:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        The transfer of cells or genetic elements (eg, DNA, RNA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        The use of pharmacological or biological agents that alter gene expression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Peroxisome Proliferator Activated Receptor &delta; (PPAR&delta;) agonists (eg, GW 1516) and PPAR&delta;-AMP-activated protein kinase (AMPK) axis agonists (eg, AICAR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Substances and methods prohibited in-competition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Stimulants*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Non-specified stimulants:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Adrafinil",
"       </td>",
"       <td>",
"        Cocaine",
"       </td>",
"       <td>",
"        Furfenorex",
"       </td>",
"       <td>",
"        Norfenfluramine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Amfepramone",
"       </td>",
"       <td>",
"        Cropropamide",
"       </td>",
"       <td>",
"        Mefenorex",
"       </td>",
"       <td>",
"        Phendimetrazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Amiphenazole",
"       </td>",
"       <td>",
"        Crotetamide",
"       </td>",
"       <td>",
"        Mephentermine",
"       </td>",
"       <td>",
"        Phenmetrazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Amphetamine",
"       </td>",
"       <td>",
"        Dimethylamphetamine",
"       </td>",
"       <td>",
"        Mesocarb",
"       </td>",
"       <td>",
"        Phentermine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Amphetaminil",
"       </td>",
"       <td>",
"        Etilamphetamine",
"       </td>",
"       <td>",
"        Methamphetamine(d-)",
"       </td>",
"       <td>",
"        4-phenylpiracetam(carphedon)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Benfluorex",
"       </td>",
"       <td>",
"        Famprofazone",
"       </td>",
"       <td>",
"        P-methylamphetamine",
"       </td>",
"       <td>",
"        Prenylamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Benzphetamine",
"       </td>",
"       <td>",
"        Fencamine",
"       </td>",
"       <td>",
"        Methylenedioxyamphetamine",
"       </td>",
"       <td>",
"        Prolintane",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Benzylpiperazine",
"       </td>",
"       <td>",
"        Fenetylline",
"       </td>",
"       <td>",
"        Methylenedioxymethamphetamine",
"       </td>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Bromantan",
"       </td>",
"       <td>",
"        Fenfluramine",
"       </td>",
"       <td>",
"        Methylhexaneamine (dimethylpentylamine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Clobenzorex",
"       </td>",
"       <td>",
"        Fenproporex",
"       </td>",
"       <td>",
"        Modafinil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        A stimulant not expressly listed in this section is a specified substance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Specified stimulants (examples):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Adrenaline&bull;",
"       </td>",
"       <td>",
"        Heptaminol",
"       </td>",
"       <td>",
"        Norfenefrine",
"       </td>",
"       <td>",
"        Propylhexedrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cathine&Delta;",
"       </td>",
"       <td>",
"        Isometheptene",
"       </td>",
"       <td>",
"        Octopamine",
"       </td>",
"       <td>",
"        Pseudoephedrine&sect;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Ephedrine&loz;",
"       </td>",
"       <td>",
"        Levmetamphetamine",
"       </td>",
"       <td>",
"        Oxilofrine",
"       </td>",
"       <td>",
"        Selegiline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Etamivan",
"       </td>",
"       <td>",
"        Meclofenoxate",
"       </td>",
"       <td>",
"        Parahydroxyamphetamine",
"       </td>",
"       <td>",
"        Sibutramine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Etilefrine",
"       </td>",
"       <td>",
"        Methylephedrine&loz;",
"       </td>",
"       <td>",
"        Pemoline",
"       </td>",
"       <td>",
"        Strychnine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Fenbutrazate",
"       </td>",
"       <td>",
"        Methylphenidate",
"       </td>",
"       <td>",
"        Pentetrazol",
"       </td>",
"       <td>",
"        Tuaminoheptane",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Fencamfamin",
"       </td>",
"       <td>",
"        Nikethamide",
"       </td>",
"       <td>",
"        Phenpromethamine",
"       </td>",
"       <td>",
"        Other substances with a similar chemical structure or similar biological effect(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Narcotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Buprenorphine",
"       </td>",
"       <td>",
"        Fentanyl and its derivatives",
"       </td>",
"       <td>",
"        Morphine",
"       </td>",
"       <td>",
"        Pentazocine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Dextromoramide",
"       </td>",
"       <td>",
"        Hydromorphone",
"       </td>",
"       <td>",
"        Oxycodone",
"       </td>",
"       <td>",
"        Pethidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Diamorphine (heroin)",
"       </td>",
"       <td>",
"        Methadone",
"       </td>",
"       <td>",
"        Oxymorphone",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Cannabinoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Natural or synthetic &Delta;9-tetrahydrocannabinol (THC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        THC-like cannabinoids (eg, hashish, marijuana, HU-210)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Glucocorticosteroids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        <p>",
"         All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular, or rectal routes.",
"        </p>",
"        <p>",
"         In accordance with the international standard for Therapeutic Use Exemptions, declaration of use must be completed by the athlete for glucocorticosteroids administered by intraarticular, periarticular, peritendinous, epidural, intradermal, and inhalation routes, except as noted below.",
"        </p>",
"        <p>",
"         Topical preparations when used for auricular, buccal, dermatological (including iontophoresis/phonophoresis), gingival, nasal, ophthalmic, and perianal disorders are not prohibited and require neither a Therapeutic Use Exemption nor a declaration of use.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Substances prohibited in particular sports",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Alcohol (ethanol) is prohibited",
"        <strong>",
"         in-competition only",
"        </strong>",
"        , in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (hematological values) is 0.10 g/L.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Aeronautic (FAI)",
"       </td>",
"       <td>",
"        Automobile (FIA)",
"       </td>",
"       <td>",
"        Modern pentathlon (UIPM) for disciplines involving shooting",
"       </td>",
"       <td>",
"        Ninepin and tenpin bowling (FIQ)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Archery (FITA)",
"       </td>",
"       <td>",
"        Karate (WKF)",
"       </td>",
"       <td>",
"        Motorcycling (FIM)",
"       </td>",
"       <td>",
"        Powerboating (UIM)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Beta-blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Beta-blockers include, but are not limited to, the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Acebutolol",
"       </td>",
"       <td>",
"        Bunolol",
"       </td>",
"       <td>",
"        Labetalol",
"       </td>",
"       <td>",
"        Oxprenolol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Alprenolol",
"       </td>",
"       <td>",
"        Carteolol",
"       </td>",
"       <td>",
"        Levobunolol",
"       </td>",
"       <td>",
"        Pindolol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Atenolol",
"       </td>",
"       <td>",
"        Carvedilol",
"       </td>",
"       <td>",
"        Metipranolol",
"       </td>",
"       <td>",
"        Propranolol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Betaxolol",
"       </td>",
"       <td>",
"        Celiprolol",
"       </td>",
"       <td>",
"        Metoprolol",
"       </td>",
"       <td>",
"        Sotalol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Bisoprolol",
"       </td>",
"       <td>",
"        Esmolol",
"       </td>",
"       <td>",
"        Nadolol",
"       </td>",
"       <td>",
"        Timolol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Unless otherwise specified, beta-blockers are prohibited",
"        <strong>",
"         in-competition only",
"        </strong>",
"        , in the following sports:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Aeronautic (FAI)",
"       </td>",
"       <td>",
"        Bobsleigh (FIBT)",
"       </td>",
"       <td>",
"        Modern pentathlon (UIPM) for disciplines involving shooting",
"       </td>",
"       <td>",
"        Shooting (ISSF, IPC) (also prohibited out-of-competition)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Archery (FITA) (also prohibited out-of-competition)",
"       </td>",
"       <td>",
"        Bridge (FMB)",
"       </td>",
"       <td>",
"        Motorcycling (FIM)",
"       </td>",
"       <td>",
"        Skiing/snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Automobile (FIA)",
"       </td>",
"       <td>",
"        Curling (WCF)",
"       </td>",
"       <td>",
"        Ninepin and tenpin bowling (FIQ)",
"       </td>",
"       <td>",
"        Wrestling (FILA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Billiards and snooker (WCBS)",
"       </td>",
"       <td>",
"        Golf (IGF)",
"       </td>",
"       <td>",
"        Powerboating (UIM)",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Boules (CMSB)",
"       </td>",
"       <td>",
"        Gymnastics (FIG)",
"       </td>",
"       <td>",
"        Sailing (ISAF) for match race helms only",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The following substances included in the 2010 Monitoring Program (bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradol, synephrine) are not considered Prohibited Substances.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Adrenaline associated with local anaesthetic agents or by local administration (eg, nasal, ophthalmologic) is not prohibited.",
"      <br>",
"       &Delta; Cathine is prohibited when its concentration in urine is greater than 5 mcg/mL.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 mcg/mL.",
"        <br>",
"         &sect; Pseudoephedrine is prohibited when its concentration in urine is greater than 150 mcg/mL.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: World Anti-Doping Agency. The World Anti-Doping Code: The 2010 Prohibited List, International Standard.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13025=[""].join("\n");
var outline_f12_46_13025=null;
var title_f12_46_13026="Radiopaque foreign body";
var content_f12_46_13026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Radiopaque foreign body in the esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiopaque foreign body retrieved from the trachea of a one-year-old child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13026=[""].join("\n");
var outline_f12_46_13026=null;
var title_f12_46_13027="Thiazides versus loop diuretics in treatment of hypertension";
var content_f12_46_13027=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thiazides versus loop diuretics in treatment of hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/46/13027/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/46/13027/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/46/13027/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/46/13027/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/46/13027/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/46/13027/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/46/13027/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretics lower the blood pressure at least initially by inducing sodium and fluid loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15350?source=see_link\">",
"     \"Use of thiazide diuretics in patients with primary hypertension\"",
"    </a>",
"    .) When used in patients with primary hypertension and relatively normal renal function, the thiazide diuretics, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13027/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], have a longer antihypertensive effect than the loop diuretics [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13027/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism is probably related to the short duration of action of the loop diuretics",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/9/43158?source=see_link\">",
"     bumetanide",
"    </a>",
"    (less than six hours), since the initial fluid loss can be counteracted by activation of the renin-angiotensin-aldosterone system, leading to sodium retention during the period when the diuretic effect has worn off [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13027/abstract/4\">",
"     4",
"    </a>",
"    ]. Longer-acting loop diuretics are available;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/13/28886?source=see_link\">",
"     torsemide",
"    </a>",
"    , for example, has a duration of action up to 12 hours. It is not known if the antihypertensive effect of torsemide is greater than that of furosemide or bumetanide.",
"   </p>",
"   <p>",
"    The two classes of diuretics also have differing effects on calcium balance:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The thiazides tend to promote calcium retention",
"     </li>",
"     <li>",
"      The loop diuretics enhance urinary calcium loss",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link\">",
"     \"Diuretics and calcium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The above observations do not necessarily apply to patients with renal insufficiency, a setting in which thiazides are less effective in competing with accumulating organic acids [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13027/abstract/5\">",
"     5",
"    </a>",
"    ]. In such patients, fluid retention frequently plays a major role in the elevation in blood pressure and the thiazides become less effective when the GFR falls below 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13027/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, a loop diuretic is more effective as an antihypertensive agent in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7337?source=see_link\">",
"     \"Overview of hypertension in acute and chronic kidney disease\"",
"    </a>",
"    .)&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/32/1542?source=see_link\">",
"     Metolazone",
"    </a>",
"    , which acts in multiple renal sites, is also effective in patients with renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13027/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OTHER DIURETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potassium-sparing agents",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    have a minimal antihypertensive effect and are not widely used as initial therapy for primary hypertension. By comparison, the aldosterone antagonists",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    (with which there is the widest experience as monotherapy) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    are more potent antihypertensive agent. In view of their apparent ability to reduce cardiac and renal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13027/abstract/8\">",
"     8",
"    </a>",
"    ], aldosterone antagonists may become much more widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13027/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29031?source=see_link\">",
"     \"Treatment of hypertension in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diuretics lower the blood pressure by inducing sodium and fluid loss. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with normal renal function, thiazide diuretics, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      , have a greater antihypertensive effect than the loop diuretics. This may be related to the longer duration of action of thiazide compared to most loop diuretics. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thiazide and loop diuretics have opposite effects on calcium balance; whereas thiazides promote calcium retention, loop diuretics enhance urinary calcium loss. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link\">",
"       \"Diuretics and calcium balance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thiazides are less effective among patients with glomerular filtration rate &lt; 30",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13027/abstract/1\">",
"      Kaplan NM. The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide. Hypertension 2009; 54:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13027/abstract/2\">",
"      Dorsch MP, Gillespie BW, Erickson SR, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13027/abstract/3\">",
"      Dussol B, Moussi-Frances J, Morange S, et al. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 2005; 20:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13027/abstract/4\">",
"      Kelly RA, Wilcox CS, Mitch WE, et al. Response of the kidney to furosemide. II. Effect of captopril on sodium balance. Kidney Int 1983; 24:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13027/abstract/5\">",
"      Brater DC. Pharmacology of diuretics. Am J Med Sci 2000; 319:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13027/abstract/6\">",
"      REUBI FC, COTTIER PT. Effects of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics. Circulation 1961; 23:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13027/abstract/7\">",
"      Paton RR, Kane RE. Long-term diuretic therapy with metolazone of renal failure and the nephrotic syndrome. J Clin Pharmacol 1977; 17:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13027/abstract/8\">",
"      Kuster GM, Kotlyar E, Rude MK, et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005; 111:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13027/abstract/9\">",
"      White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13027/abstract/10\">",
"      Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005; 18:50.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3871 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13027=[""].join("\n");
var outline_f12_46_13027=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OTHER DIURETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=related_link\">",
"      Diuretics and calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29031?source=related_link\">",
"      Treatment of hypertension in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15350?source=related_link\">",
"      Use of thiazide diuretics in patients with primary hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_46_13028="Left colectomy for malignancy";
var content_f12_46_13028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left colectomy for malignancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 544px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the extensive resection of a left colon cancer. Note the ligation of the inferior mesenteric artery at its origin from the aorta and the ligation of the inferior mesenteric vein near the distal pancreas. A minimum 5 centimeter margin is obtained both proximal and distal to the malignant lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13028=[""].join("\n");
var outline_f12_46_13028=null;
var title_f12_46_13029="Cetirizine and pseudoephedrine: Patient drug information";
var content_f12_46_13029=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cetirizine and pseudoephedrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35253?source=see_link\">",
"     see \"Cetirizine and pseudoephedrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ZyrTEC-D&reg; Allergy &amp; Congestion [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F148881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Reactine&reg; Allergy and Sinus",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701758",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cetirizine, hydroxyzine, pseudoephedrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703506",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Trouble passing urine, glaucoma, very bad heart disease, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11186 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-D3F1CA963C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13029=[""].join("\n");
var outline_f12_46_13029=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148880\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148881\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018656\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018658\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018657\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018662\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018663\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018665\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018660\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018661\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018666\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018667\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35253?source=related_link\">",
"      Cetirizine and pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_46_13030="Clinical manifestations and diagnosis of HIV-2 infection";
var content_f12_46_13030=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of HIV-2 infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/46/13030/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/46/13030/contributors\">",
"     Geoffrey S Gottlieb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/46/13030/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/46/13030/contributors\">",
"     John A Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/46/13030/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/46/13030/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/46/13030/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15783692\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HIV-1 infection is associated with most of the global AIDS pandemic, HIV-2 is an important cause of disease in certain regions of the world where it is endemic. HIV-2 infection has also been described in pockets of locations globally, so it is an important consideration in patients with an AIDS-like illness or among persons with epidemiologic risk factors for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/1\">",
"     1",
"    </a>",
"    ]. Epidemiologic risk factors are also similar to HIV-1 infection and include a past history of blood transfusion or having a sex partner or needle-sharing partner with HIV-2 infection.",
"   </p>",
"   <p>",
"    This topic will address the clinical manifestations and diagnosis of HIV-2 infection. The epidemiology, transmission, natural history, pathogenesis and treatment of HIV-2 are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38343?source=see_link\">",
"     \"Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26713?source=see_link\">",
"     \"Treatment of HIV-2 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605658\">",
"    <span class=\"h1\">",
"     STAGING OF DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In HIV-1 infected patients, two important laboratory determinants of the rate of progression are the CD4 cell count and the plasma viral load [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In untreated patients, the average rate of decline of CD4 cells (\"CD4 slope\") is about",
"    <span class=\"nowrap\">",
"     50/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    per year and the average viral burden (without therapy) is 30,000 to 50,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Patients with a CD4 cell count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    are considered to have AIDS; such patients are at significantly increased risk for opportunistic infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=see_link\">",
"     \"Factors affecting HIV progression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are far fewer data on the CD4 threshold that is associated with an increased risk of AIDS and opportunistic infections among HIV-2 infected patients. Most experts apply the same CD4 cell count threshold (&lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    as a laboratory parameter indicating AIDS in HIV-2 infected patients.",
"   </p>",
"   <p>",
"    Laboratory monitoring for HIV-2 RNA is problematic since testing availability in limited. Most commercial laboratories do not offer testing for HIV-2 RNA and the few that do offer only qualitative testing (eg, FOCUS and QUEST laboratories). Quantitative HIV-2 RNA testing may be obtained from the following few laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, contact Geoffrey Gottlieb at the University of Washington (gottlieb@uw.edu) or UW Lab Medicine Community Services (phone 800-713-5198 or commserv@u.washington.edu)",
"     </li>",
"     <li>",
"      In Europe, contacts are available at",
"      <a class=\"external\" href=\"file://etudes.isped.u-bordeaux2.fr/achiev2e\">",
"       file://etudes.isped.u-bordeaux2.fr/achiev2e",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some research laboratories that perform HIV-2 RNA quantitative testing report generally lower levels of HIV viremia compared with patients with HIV-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/8-12\">",
"     8-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605843\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR CLINICAL PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors contribute to HIV-1 disease progression including viral fitness, genetic factors, HIV coreceptor usage, nutritional status, as well as other comorbidities. However, the cofactors that lead to progression of HIV-2 infection are not well understood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=see_link&amp;anchor=H5#H5\">",
"     \"Factors affecting HIV progression\", section on 'Rate of progression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15783699\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605740\">",
"    <span class=\"h2\">",
"     Primary HIV-2 infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are scant data on the clinical presentation of acute HIV-2 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605774\">",
"    <span class=\"h2\">",
"     Chronic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with HIV-1, HIV-2 infection is characterized by a longer asymptomatic stage of infection and slower declines of CD4+ T-cell counts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/8-12,15-24\">",
"     8-12,15-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38343?source=see_link\">",
"     \"Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the clinical manifestations of advanced HIV-2 infection are generally similar to those reported for HIV-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/25\">",
"     25",
"    </a>",
"    ]. Once advanced immunosuppression has occurred (eg, CD4 cell count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ),",
"    </span>",
"    HIV-2 infected patients are at risk for similar types of opportunistic infections, such as pneumocystis and cryptococcal disease. Although some studies have suggested that there may be some subtle differences in the frequencies of reported opportunistic infections in HIV-2 infected patients, these observational data are limited by small numbers of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/26-31\">",
"     26-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The history and physical examination for the HIV-2 infected patient should be detailed and extensive, similar to that of the HIV-1 infected patient, as discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26474?source=see_link\">",
"     \"Primary care of HIV-infected adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15783706\">",
"    <span class=\"h1\">",
"     TESTING FOR HIV-2 INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in HIV-1 infection, patients should have serologic testing for HIV-2 infection with confirmatory testing. Although most serologic tests detect both HIV-1 and HIV-2, the majority of assays do not differentiate between the two viruses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15783720\">",
"    <span class=\"h2\">",
"     Which tests to order?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only screening antibody test that detects and differentiates HIV-2 infection from HIV-1 is the Multispot",
"    <span class=\"nowrap\">",
"     HIV-1/HIV-2",
"    </span>",
"    Rapid Test (Bio-Rad Laboratories) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/32\">",
"     32",
"    </a>",
"    ]. A reactive result should be confirmed with a supplemental HIV-2 antibody test. Supplemental testing can include either:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An HIV-2 specific immunoblot assay (eg, Western blot)",
"     </li>",
"     <li>",
"      An HIV-2 specific enzyme immunoassay",
"     </li>",
"     <li>",
"      Real-time polymerase chain reaction (RT-PCR) testing for the viral isolate itself",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supplemental HIV-2 testing is available through the CDC or may be obtained through commercial testing laboratories, such as Focus Diagnostics or Quest Diagnostics in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Qualitative HIV-2 RNA through RT-PCR testing can be obtained through Focus Diagnostics [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/35\">",
"     35",
"    </a>",
"    ]. Quantitative HIV-2 RNA testing may be obtained as noted above.",
"   </p>",
"   <p>",
"    Outside of the United States, supplemental HIV-2 antibody assays that are commercially available include: Immunocomb II (Orgenics), Genie II (Biorad), SD Bioline (Standard Diagnostics), INNO-LIA HIV",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    Score (Innogenetics NV) and HIV-2 Blot (MP Biomedials, LLC).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15783734\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC ISSUES RELATED TO HIV-1 WESTERN BLOT TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605877\">",
"    <span class=\"h2\">",
"     General background",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians need to be aware that all commercially available HIV-1 Western Blot assays may fully or partially cross-react with HIV-2, giving positive, indeterminate, or negative results that could lead to an incorrect diagnosis of HIV-1 infection or a missed diagnosis of HIV-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These diagnostic issues were well illustrated by results of an HIV-2 surveillance survey performed by the CDC in 2009, where the vast majority of cases were suspected because of inconsistent clinical or laboratory data [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/38\">",
"     38",
"    </a>",
"    ]. Of 166 cases with HIV-2 infection, 56 percent of patients had an indeterminate HIV-1 immunoblot despite a positive HIV-1 or",
"    <span class=\"nowrap\">",
"     HIV-1/HIV-2",
"    </span>",
"    antibody screening test; 41 percent had an undetectable HIV viral load despite a positive HIV-1 immunoblot; and less than 1 percent had a negative HIV-1 immunoblot despite a positive HIV-1 or",
"    <span class=\"nowrap\">",
"     HIV-1/HIV-2",
"    </span>",
"    antibody screening test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605884\">",
"    <span class=\"h2\">",
"     Interpretation of Western blot test results",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion addresses the interpretation and evaluation of various possible HIV immunoblot assay results in the patient with suspected HIV-2 infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15783741\">",
"    <span class=\"h3\">",
"     A reactive HIV-1 Western blot",
"    </span>",
"    &nbsp;&mdash;&nbsp;A confirmatory Western blot for HIV-1 can be reactive due to true infection with HIV-1 or cross-reactivity to HIV-2 proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, this laboratory profile can represent three possible scenarios: monoinfection with HIV-1, monoinfection with HIV-2, or dual infection with both viruses.",
"   </p>",
"   <p>",
"    If HIV-2 infection is suspected (eg, the patient is from West Africa), further testing with a specific HIV-2 Western blot is recommended. If the HIV-2 Western blot is negative, the patient can be assumed to have HIV-1 monoinfection. If the HIV-2 Western blot is reactive, the patient may have monoinfection with HIV-2 or dual infection with both HIV-1 and HIV-2. Further testing for HIV-1",
"    <span class=\"nowrap\">",
"     RNA/DNA",
"    </span>",
"    and HIV-2",
"    <span class=\"nowrap\">",
"     RNA/DNA",
"    </span>",
"    should be performed. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15783748\">",
"    <span class=\"h3\">",
"     An indeterminate HIV-1 Western blot",
"    </span>",
"    &nbsp;&mdash;&nbsp;An indeterminate Western blot can infer acute HIV-1 infection or chronic HIV-2 infection. Further testing for HIV-1 RNA is indicated for the possibility of acute HIV-1 infection; if HIV-1 RNA is not detected, then HIV-2 Western blot testing and HIV-2",
"    <span class=\"nowrap\">",
"     RNA/DNA",
"    </span>",
"    should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15783755\">",
"    <span class=\"h3\">",
"     A negative HIV-1 Western blot",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient with a reactive HIV serology, but a negative confirmatory HIV-1 Western blot, may have HIV-2 infection. Thus, further testing with a specific HIV-2 Western blot should be performed, particularly in persons with epidemiologic risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15783769\">",
"    <span class=\"h1\">",
"     WHEN TO SUSPECT HIV-2 INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians must have a high index of suspicion for the diagnosis of HIV-2 infection since laboratory testing results can lead to diagnostic confusion, as discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Patients with a diagnosis of HIV-1 infection may actually be infected with HIV-2 or may be dually infected with both viruses. Certain clinical or laboratory clues should lead to further patient evaluation and testing, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15783783\">",
"    <span class=\"h2\">",
"     Clinical clues to possible HIV-2 infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-2 diagnostic testing should be considered when clinical or laboratory data are incongruent, as described in the following scenarios [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patient from an HIV-2 endemic area, who presents with an opportunistic infection (eg, pneumocystis) or an AIDS-related clinical condition, and is found to be HIV-1 seronegative",
"     </li>",
"     <li>",
"      An HIV-seropositive patient with no detectable plasma HIV-1 RNA on ART who has a declining CD4 cell count",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15783790\">",
"    <span class=\"h2\">",
"     Laboratory clues for possible HIV-2 infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-2 infection may also be suspected in the following scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An untreated HIV-seropositive patient who has a low or undetectable viral load &nbsp;",
"     </li>",
"     <li>",
"      An HIV-seropositive patient with a virus that cannot be genotyped on routine HIV drug resistance testing",
"     </li>",
"     <li>",
"      An HIV-seropositive patient with a Western blot test that is reported as &ldquo;indeterminate&rdquo;. An indeterminate Western blot is characterized by an unusual pattern of HIV proteins (such as HIV &ldquo;gag&rdquo; plus &ldquo;pol&rdquo; without &ldquo;env&rdquo;). (See",
"      <a class=\"local\" href=\"#H15783748\">",
"       'An indeterminate HIV-1 Western blot'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15783797\">",
"    <span class=\"h1\">",
"     WHO SHOULD BE SCREENED?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control (CDC) also recommends screening for HIV-2 infection in asymptomatic persons who are at risk for HIV-2 infection, including [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13030/abstract/1,37\">",
"     1,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persons from endemic areas",
"     </li>",
"     <li>",
"      Sex partners and needle-sharing partners of persons with a diagnosis of HIV-2 infection &nbsp;",
"     </li>",
"     <li>",
"      Sex partners and needle-sharing partners of persons from endemic areas",
"     </li>",
"     <li>",
"      Children of women with a diagnosis of HIV-2 or risk factors for HIV-2 infection",
"     </li>",
"     <li>",
"      Persons with a history of a blood transfusion in an endemic area &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Locales where the prevalence of HIV-2 infection is considered &ldquo;endemic&rdquo; include all countries in West Africa: Benin, Burkina-Faso, Cape Verde, Cote d&rsquo;Ivoire (Ivory Coast), Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, and Togo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15783818\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations of advanced HIV-2 infection are generally similar to those reported for HIV-1. Once advanced immunosuppression has occurred (eg, CD4 cell count &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ),",
"      </span>",
"      HIV-2 infected patients are at risk for similar types of opportunistic infections, such as pneumocystis and cryptococcal disease. (See",
"      <a class=\"local\" href=\"#H15783699\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The only HIV antibody test approved by the Food and Drug Administration that detects and differentiates HIV-2 infection from HIV-1 is the Multispot",
"      <span class=\"nowrap\">",
"       HIV-1/HIV-2",
"      </span>",
"      Rapid Test. A reactive result should be confirmed with a supplemental HIV-2 antibody test, such as an HIV-2 specific Western blot assay. (See",
"      <a class=\"local\" href=\"#H15783706\">",
"       'Testing for HIV-2 infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The possibility of HIV-2 infection should be considered in: a) persons from an endemic area who present with an AIDS-like illness, b) an untreated HIV-seropositive patient with a low or non-detectable viral load, or c) an HIV-seropositive patient with no detectable HIV RNA with declining immunity despite antiretroviral therapy. (See",
"      <a class=\"local\" href=\"#H15783769\">",
"       'When to suspect HIV-2 infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-2 screening should be considered among asymptomatic persons who are at risk of infection. Such persons include those who have lived in endemic areas or who are sexual partners or needle-sharing partners of persons at risk for HIV-2 infection. (See",
"      <a class=\"local\" href=\"#H15783797\">",
"       'Who should be screened?'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/1\">",
"      Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 2011; 52:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/2\">",
"      Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/3\">",
"      Mellors JW, Mu&ntilde;oz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/4\">",
"      Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA 1998; 279:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/5\">",
"      Damond F, Benard A, Ruelle J, et al. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J Clin Microbiol 2008; 46:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/6\">",
"      Damond F, Benard A, Balotta C, et al. An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study. J Clin Microbiol 2011; 49:3491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/7\">",
"      Chang M, Gottlieb GS, Dragavon JA, et al. Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform. J Clin Virol 2012; 55:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/8\">",
"      Prazuck T, Yameogo JM, Heylinck B, et al. Mother-to-child transmission of human immunodeficiency virus type 1 and type 2 and dual infection: a cohort study in Banfora, Burkina Faso. Pediatr Infect Dis J 1995; 14:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/9\">",
"      Gottlieb GS, Hawes SE, Agne HD, et al. Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS 2006; 20:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/10\">",
"      Burgard M, Jasseron C, Matheron S, et al. Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1. Clin Infect Dis 2010; 51:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/11\">",
"      Hawes SE, Sow PS, Stern JE, et al. Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding. AIDS 2008; 22:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/12\">",
"      Simon F, Matheron S, Tamalet C, et al. Cellular and plasma viral load in patients infected with HIV-2. AIDS 1993; 7:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/13\">",
"      Christiansen CB, Jessen TE, Nielsen C, Staun-Olsen P. False negative anti-HIV-1/HIV-2 ELISAs in acute HIV-2 infection. Vox Sang 1996; 70:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/14\">",
"      Besnier JM, Barin F, Baillou A, et al. Symptomatic HIV-2 primary infection. Lancet 1990; 335:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/15\">",
"      Kanki PJ, Travers KU, MBoup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/16\">",
"      Comparison of vertical human immunodeficiency virus type 2 and human immunodeficiency virus type 1 transmission in the French prospective cohort. The HIV Infection in Newborns French Collaborative Study Group. Pediatr Infect Dis J 1994; 13:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/17\">",
"      Adjorlolo-Johnson G, De Cock KM, Ekpini E, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994; 272:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/18\">",
"      Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/19\">",
"      Gottlieb GS, Sow PS, Hawes SE, et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002; 185:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/20\">",
"      Gilbert PB, McKeague IW, Eisen G, et al. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med 2003; 22:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/21\">",
"      MacNeil A, Sarr AD, Sankal&eacute; JL, et al. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 2007; 81:5325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/22\">",
"      Popper SJ, Sarr AD, Travers KU, et al. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999; 180:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/23\">",
"      Poulsen AG, Aaby P, Larsen O, et al. 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet 1997; 349:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/24\">",
"      Martinez-Steele E, Awasana AA, Corrah T, et al. Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS 2007; 21:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/25\">",
"      1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/26\">",
"      Ndour M, Sow PS, Coll-Seck AM, et al. AIDS caused by HIV1 and HIV2 infection: are there clinical differences? Results of AIDS surveillance 1986-97 at Fann Hospital in Dakar, Senegal. Trop Med Int Health 2000; 5:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/27\">",
"      De Cock KM, Odehouri K, Colebunders RL, et al. A comparison of HIV-1 and HIV-2 infections in hospitalized patients in Abidjan, C&ocirc;te d'Ivoire. AIDS 1990; 4:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/28\">",
"      Matheron S, Mendoza-Sassi G, Simon F, et al. HIV-1 and HIV-2 AIDS in African patients living in Paris. AIDS 1997; 11:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/29\">",
"      Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a west African city. AIDS 1993; 7:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/30\">",
"      Ariyoshi K, Schim van der Loeff M, Cook P, et al. Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8. J Hum Virol 1998; 1:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/31\">",
"      Hawes SE, Critchlow CW, Faye Niang MA, et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis 2003; 188:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/32\">",
"      Greenwald JL, Burstein GR, Pincus J, Branson B. A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep 2006; 8:125.",
"     </a>",
"    </li>",
"    <li>",
"     file://etd.paml.com/etd/display.php?ordercode=HIV2WB&amp;and=&amp;andand= (Accessed on September 30, 2011).",
"    </li>",
"    <li>",
"     file://www.questdiagnostics.com/hcp/intguide/jsp/showintguidepage.jsp?fn=HIV/XX_HIV-1_Infection.htm (Accessed on September 30, 2011).",
"    </li>",
"    <li>",
"     file://www.focusdx.com/focus/1-reference_laboratory/search_frame.asp?searchOptionScope=2&amp;S1=1&amp;S2=1&amp;test=&amp;sp=49000&amp;Keyword=HIV-2 DNA/RNA Qualitative Real-Time PCR#an_49000 (Accessed on September 30, 2011).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/hiv/resources/factsheets/hiv2.htm (Accessed on March 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/37\">",
"      O'Brien TR, George JR, Epstein JS, et al. Testing for antibodies to human immunodeficiency virus type 2 in the United States. MMWR Recomm Rep 1992; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/38\">",
"      Centers for Disease Control and Prevention (CDC). HIV-2 Infection Surveillance--United States, 1987-2009. MMWR Morb Mortal Wkly Rep 2011; 60:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13030/abstract/39\">",
"      Gottlieb GS, Smith RA, Sow PS. Long-term nonprogressive disease among individuals with untreated HIV infection. JAMA 2010; 304:1784; author reply 1785.",
"     </a>",
"    </li>",
"    <li>",
"     file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (Accessed on October 17, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16727 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13030=[""].join("\n");
var outline_f12_46_13030=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15783818\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15783692\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H605658\">",
"      STAGING OF DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H605843\">",
"      RISK FACTORS FOR CLINICAL PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15783699\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H605740\">",
"      Primary HIV-2 infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H605774\">",
"      Chronic infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15783706\">",
"      TESTING FOR HIV-2 INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15783720\">",
"      Which tests to order?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15783734\">",
"      DIAGNOSTIC ISSUES RELATED TO HIV-1 WESTERN BLOT TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H605877\">",
"      General background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H605884\">",
"      Interpretation of Western blot test results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15783741\">",
"      - A reactive HIV-1 Western blot",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15783748\">",
"      - An indeterminate HIV-1 Western blot",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15783755\">",
"      - A negative HIV-1 Western blot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15783769\">",
"      WHEN TO SUSPECT HIV-2 INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15783783\">",
"      Clinical clues to possible HIV-2 infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15783790\">",
"      Laboratory clues for possible HIV-2 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15783797\">",
"      WHO SHOULD BE SCREENED?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15783818\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38343?source=related_link\">",
"      Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=related_link\">",
"      Factors affecting HIV progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26474?source=related_link\">",
"      Primary care of HIV-infected adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26713?source=related_link\">",
"      Treatment of HIV-2 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_46_13031="Amantadine: Drug information";
var content_f12_46_13031=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amantadine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/53/3925?source=see_link\">",
"    see \"Amantadine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/62/17383?source=see_link\">",
"    see \"Amantadine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dom-Amantadine;",
"     </li>",
"     <li>",
"      Mylan-Amantadine;",
"     </li>",
"     <li>",
"      PHL-Amantadine;",
"     </li>",
"     <li>",
"      PMS-Amantadine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F132715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Parkinson's Agent, Dopamine Agonist;",
"     </li>",
"     <li>",
"      Antiviral Agent;",
"     </li>",
"     <li>",
"      Antiviral Agent, Adamantane",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F132679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Influenza A treatment/prophylaxis:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Due to issues of resistance, amantadine is no longer recommended for the treatment or prophylaxis of influenza A. Please refer to the current ACIP recommendations. The following is based on the manufacturer&rsquo;s labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Influenza A treatment:",
"     </i>",
"     Oral: 200 mg once daily",
"     <b>",
"      or",
"     </b>",
"     100 mg twice daily (may be preferred to reduce CNS effects);",
"     <b>",
"      Note:",
"     </b>",
"     Initiate within 24-48 hours after onset of symptoms; continue for 24-48 hours after symptom resolution (duration of therapy is generally 3-5 days).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Influenza A prophylaxis:",
"     </i>",
"     Oral: 200 mg once daily",
"     <b>",
"      or",
"     </b>",
"     100 mg twice daily (may be preferred to reduce CNS effects).",
"     <b>",
"      Note:",
"     </b>",
"     Continue prophylaxis throughout the peak influenza activity in the community or throughout the entire influenza season in patients who cannot be vaccinated. Development of immunity following vaccination takes ~2 weeks; amantadine therapy should be considered for high-risk patients from the time of vaccination until immunity has developed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Drug-induced extrapyramidal symptoms:",
"     </b>",
"     Oral: 100 mg twice daily; may increase to 300 mg/day in divided doses, if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Parkinson's disease:",
"     </b>",
"     Oral: Usual dose: 100 mg twice daily as monotherapy; may increase to 400 mg/day in divided doses, if needed, with close monitoring.",
"     <b>",
"      Note:",
"     </b>",
"     Patients with a serious concomitant illness or those receiving high doses of other anti-parkinson drugs should be started at 100 mg/day; may increase to 100 mg twice daily, if needed, after one to several weeks.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F132695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/62/17383?source=see_link\">",
"      see \"Amantadine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Influenza A treatment/prophylaxis:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Due to issues of resistance, amantadine is no longer recommended for the treatment or prophylaxis of influenza A.  Please refer to the current ACIP recommendations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Influenza A treatment:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-9 years: 5 mg/kg/day in 2 divided doses (manufacturer's range: 4.4-8.8 mg/kg/day); maximum dose: 150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;10 years and &lt;40 kg: 5 mg/kg/day in 2 divided doses (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;10 years and &ge;40 kg: 100 mg twice daily (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Initiate within 24-48 hours after onset of symptoms; continue for 24-48 hours after symptom resolution (duration of therapy is  generally 3-5 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Influenza A prophylaxis:",
"     </i>",
"     Refer to &ldquo;Influenza A treatment&rdquo; dosing.",
"     <b>",
"      Note:",
"     </b>",
"     Continue prophylaxis throughout the peak influenza activity in the community or throughout the entire influenza season in patients who cannot be vaccinated. Development of immunity following vaccination takes ~2 weeks; amantadine therapy should be considered for high-risk patients from the time of vaccination until immunity has developed. For children &lt;9 years receiving influenza vaccine for the first time, amantadine prophylaxis should continue for 6 weeks (4 weeks after the first dose and 2 weeks after the second dose).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F132680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Patients &ge;65 years: Adjust dose based on renal function; some patients tolerate the drug better when it is given in 2 divided daily doses (to avoid adverse neurologic reactions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Influenza A  treatment/prophylaxis: 100 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F132681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Administer 200 mg on day 1, then 100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-29 mL/minute: Administer 200 mg on day 1, then 100 mg on alternate days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute: Administer 200 mg every 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Administer 200 mg every 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: No supplemental dose is needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous arteriovenous or venous-venous hemofiltration: No supplemental dose is needed",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral, as hydrochloride: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride: 50 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrochloride: 50 mg/5 mL (10 mL, 473 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F132653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis and treatment of influenza A viral infection (per manufacturer labeling; also refer to current ACIP guidelines for recommendations during current flu season); treatment of parkinsonism; treatment of drug-induced extrapyramidal symptoms",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F132723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amantadine may be confused with ranitidine, rimantadine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Symmetrel may be confused with Synthroid&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F132713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, ataxia, confusion, delirium, depression, dizziness, dream abnormality, fatigue, hallucinations, headache, insomnia, irritability, lightheadedness, nervousness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Livedo reticularis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dry nose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Aggressive behavior, agranulocytosis, alkaline phosphatase increased, allergic reaction, ALT increased, AST increased, amnesia, anaphylaxis, arrhythmia, bilirubin increased, BUN increased, cardiac arrest, coma, CPK increased, creatinine increased, delusions, diaphoresis, dysphagia, dyspnea, eczematoid dermatitis, euphoria, GGT increased, heart failure, hyperkinesis, LDH increased, leukopenia, mania, neutropenia, neuroleptic malignant syndrome (NMS; associated with dosage reduction or abrupt withdrawal of amantadine), oculogyric episodes, paresthesia, photosensitivity, psychosis, pulmonary edema, rash, respiratory failure (acute), seizures, suicidal ideation, suicide, urinary retention, withdrawal reactions (may include delirium, hallucinations, and psychosis), visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reported with dopamine agonists: Impulsive/compulsive behaviors (eg, pathological gambling, hypersexuality, binge eating)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F132656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amantadine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F132639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impulse control disorders: Dopamine agonists used for Parkinson&rsquo;s disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Melanoma: Risk for melanoma development is increased in Parkinson&rsquo;s disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome: Has been associated with neuroleptic malignant syndrome (associated with dose reduction or abrupt discontinuation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: There have been reports of suicidal ideation/attempt in patients with and without a history of psychiatric illness. May exacerbate mental problems in patients with a history of mental illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with heart failure, peripheral edema, or orthostatic hypotension; dosage reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Eczema: Use with caution in patients with a history of recurrent and eczematoid dermatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Avoid in untreated angle closure glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; rarely, elevations in transaminases have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Influenza A: Appropriate use: Consult current guidelines. Due to increased resistance, the ACIP has recommended that rimantadine and amantadine no longer be used for the treatment or prophylaxis of influenza A in the United States until susceptibility has been re-established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Appropriate use: When treating Parkinson's disease, do not discontinue abruptly. In many patients, the therapeutic benefits of amantadine are limited to a few months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychosis: Use with caution in patients with uncontrolled psychosis or severe psychoneurosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage reduction recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS stimulants: Use with caution in patients receiving CNS stimulant drugs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more susceptible to CNS effects (using 2 divided daily doses may minimize this effect). These patients may require dosage reductions based on renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;1 year of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal syndrome: May cause agitation, anxiety, delirium, delusions, depression, hallucinations, paranoia, parkinsonian crisis, slurred speech, or stupor.  Upon discontinuation of amantadine therapy, gradually taper dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Atypical): May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Typical): Anti-Parkinson's Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: Amantadine may enhance the anticholinergic effect of Glycopyrrolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. Amantadine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Amantadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F132672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS adverse effects).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F132646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F132660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal studies and in case reports in humans.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Influenza infection may be more severe in pregnant women. Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complications or death to the mother. Oseltamivir and zanamivir are currently recommended for the treatment or prophylaxis influenza in pregnant women and women up to 2 weeks postpartum. Antiviral agents are currently recommended as an adjunct to vaccination and should not be used as a substitute for vaccination in pregnant women (consult current CDC guidelines).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to refer women exposed to influenza vaccine, or who have taken an antiviral medication during pregnancy to the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) by contacting The Organization of Teratology Information Specialists (OTIS) at (877) 311-8972",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F132684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11313487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The CDC recommends that women infected with the influenza virus follow general precautions (eg, frequent hand washing) to decrease viral transmission to the child. Mothers with influenza-like illnesses at delivery should consider avoiding close contact with the infant until they have received 48 hours of antiviral medication, fever has resolved, and cough and secretions can be controlled. These measures may help decrease (but not eliminate) the risk of transmitting influenza to the newborn during breast-feeding.  During this time, breast milk can be expressed and bottle-fed to the infant by another person who is not infected. Protective measures, such as wearing a face mask, changing into a clean gown or clothing, and strict hand hygiene should be continued by the mother for &ge;7 days after the onset of symptoms or until symptom-free for 24 hours. Infant care should be performed by a noninfected person when possible (consult current CDC guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F132659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Amantadine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $201.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Amantadine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/5 mL (473 mL): $70.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Amantadine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $228.33",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F132648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function, Parkinson's symptoms, mental status, influenza symptoms, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F132661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      a.m.t. (DE);",
"     </li>",
"     <li>",
"      Amanda (TW);",
"     </li>",
"     <li>",
"      Amandin (TW);",
"     </li>",
"     <li>",
"      Amandine (UY);",
"     </li>",
"     <li>",
"      Amantadin (EE);",
"     </li>",
"     <li>",
"      Amantadina Juventus (ES);",
"     </li>",
"     <li>",
"      Amantadina Llorente (ES);",
"     </li>",
"     <li>",
"      Amantan (BE, LU);",
"     </li>",
"     <li>",
"      Amantix (CO, PL);",
"     </li>",
"     <li>",
"      Amantrel (IN);",
"     </li>",
"     <li>",
"      Amazolon (JP);",
"     </li>",
"     <li>",
"      Atadin (TW);",
"     </li>",
"     <li>",
"      Atarin (CL, FI);",
"     </li>",
"     <li>",
"      Boidan (JP);",
"     </li>",
"     <li>",
"      Enzil (TW);",
"     </li>",
"     <li>",
"      Hofcomant (AT, FI);",
"     </li>",
"     <li>",
"      Influ (TW);",
"     </li>",
"     <li>",
"      Influ-A (IL);",
"     </li>",
"     <li>",
"      Mantadan (IT);",
"     </li>",
"     <li>",
"      Mantadix (FR, LU);",
"     </li>",
"     <li>",
"      Mantidan (BR);",
"     </li>",
"     <li>",
"      Parkintrel (KP);",
"     </li>",
"     <li>",
"      PK-Merz (AE, AT, BF, BG, BH, BJ, CH, CI, CN, CR, CY, CZ, DE, DO, EE, EG, ET, GH, GM, GN, GT, HK, HN, HU, IL, IQ, IR, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, OM, PA, PH, PK, PT, PY, QA, SA, SC, SD, SL, SN, SV, SY, TN, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Prayanol (CN);",
"     </li>",
"     <li>",
"      Symmetrel (AE, AU, BH, CH, CY, EG, GB, GR, HR, IE, IQ, IR, JO, KW, LB, LY, NL, NO, NZ, OM, QA, SA, SY, VE, YE);",
"     </li>",
"     <li>",
"      Viregyt-K (BG, HU);",
"     </li>",
"     <li>",
"      Virofral (DK);",
"     </li>",
"     <li>",
"      Virosol (AR);",
"     </li>",
"     <li>",
"      Zintergia (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F132638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As an antiviral, blocks the uncoating of influenza A virus preventing penetration of virus into host; antiparkinsonian activity may be due to its blocking the reuptake of dopamine into presynaptic neurons or by increasing dopamine release from presynaptic fibers",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F132655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Antidyskinetic: Within 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Normal: 1.5-6.1 L/kg; Renal failure: 5.1 &plusmn; 0.2 L/kg; in saliva, tear film, and nasal secretions; in animals, tissue (especially lung) concentrations higher than serum concentrations; crosses blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Normal renal function: ~67%; Hemodialysis: ~59%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not appreciable; small amounts of an acetyl metabolite identified",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 86% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Normal renal function: 16 &plusmn; 6 hours (9-31 hours); Healthy, older (&ge;60 years) males: 29 hours (range: 20-41 hours); End-stage renal disease: 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80% to 90% unchanged) by glomerular filtration and tubular secretion",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allen RM, &ldquo;Palliative Treatment of Tardive Dyskinesia With Combination of Amantadine-Neuroleptic Administration,&rdquo;",
"      <i>",
"       Biol Psychiatry",
"      </i>",
"      , 1982, 17(6):719-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/6179548/pubmed\" id=\"6179548\" target=\"_blank\">",
"        6179548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Alphs L and Davis JM, &ldquo;Noncatecholaminergic Treatments of Tardive Dyskinesia,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1982, 2(6):380-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/6129267/pubmed\" id=\"6129267\" target=\"_blank\">",
"        6129267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aoki FY and Sitar DS, &ldquo;Amantadine Kinetics in Healthy Elderly Men: Implications for Influenza Prevention,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1985, 37(2):137-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/3967456/pubmed\" id=\"3967456\" target=\"_blank\">",
"        3967456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aoki FY and Sitar DS, &ldquo;Clinical Pharmacokinetics of Amantadine Hydrochloride,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1988, 14(1):35-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/3280212/pubmed\" id=\"3280212\" target=\"_blank\">",
"        3280212",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Borison RL, &ldquo;Amantadine in the Management of Extrapyramidal Side Effects,&rdquo;",
"      <i>",
"       Clin Neuropharmacol",
"      </i>",
"      , 1983, 6(Suppl 1):57-63.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Influenza Division, National Center for Immunization and Respiratory Diseases. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza --- Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Surveill Summ",
"      </i>",
"      , 2011, 60(1):1-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/21248682/pubmed\" id=\"21248682\" target=\"_blank\">",
"        21248682",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Interim Guidance: Considerations Regarding 2009 Novel H1N1 Flu Virus in Intrapartum and Postpartum Hospital Settings,\"  Available at",
"      <a href=\"file://www.cdc.gov/h1n1flu/guidance/obstetric.htm\" target=\"_blank\">",
"       file://www.cdc.gov/h1n1flu/guidance/obstetric.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/12755288/pubmed\" id=\"12755288\" target=\"_blank\">",
"        12755288",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Non-HIV Viral Infections,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2002, 44(1123):9-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/11828264/pubmed\" id=\"11828264\" target=\"_blank\">",
"        11828264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Factor SA, &ldquo;Current Status of Symptomatic Medical Therapy in Parkinson&rsquo;s Disease,&rdquo;",
"      <i>",
"       Neurotherapeutics",
"      </i>",
"      , 2008, 5(2):164-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/18394561/pubmed\" id=\"18394561\" target=\"_blank\">",
"        18394561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koller WC, Silver DE, and Lieberman A, &ldquo;An Algorithm for the Management of Parkinson's Disease,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1994, 44(12 Suppl 10):1-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/8290041/pubmed\" id=\"8290041\" target=\"_blank\">",
"        8290041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Merigan KS, and Browning RG, &ldquo;Despiramine and Amantadine Causing False-Positive Urine Test for Amphetamine,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1993, 22(12):1927-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/8239121/pubmed\" id=\"8239121\" target=\"_blank\">",
"        8239121",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller KS and Miller JM, &ldquo;Toxic Effects of Amantadine in Patients With Renal Failure,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1994, 105(5):1630.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina JA, S&agrave;inz-Artiga MJ, Fraile A, et al, &ldquo;Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,&rdquo;",
"      <i>",
"       Mov Disord",
"      </i>",
"      , 2000, 15(5):869-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/11009192/pubmed\" id=\"11009192\" target=\"_blank\">",
"        11009192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poldinger W, &ldquo;Therapy of Extrapyramidal Side Effects, With Particular Reference to Persistent Dyskinesia and Lithium Tremor,&rdquo;",
"      <i>",
"       International Pharmacopsychiatry",
"      </i>",
"      , 1978, 13(4):230-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/32149/pubmed\" id=\"32149\" target=\"_blank\">",
"        32149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Somani SK, Degelau J, Cooper SL, et al, &ldquo;Comparison of Pharmacokinetic and Safety Profiles of Amantadine 50- and 100-mg Daily Doses in Elderly Nursing Home Residents,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1991, 11(6):460-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/1771145/pubmed\" id=\"1771145\" target=\"_blank\">",
"        1771145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stange KC, Little DW, and Blatnik B, &ldquo;Adverse Reactions to Amantadine Prophylaxis of Influenza in a Retirement Home,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1991, 33(7):700-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strong DK, Eisenstat DD, Bryson SM, et al, &ldquo;Amantadine Neurotoxicity in a Pediatric Patient With Renal Insufficiency,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1991, 25(11):1175-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/1763530/pubmed\" id=\"1763530\" target=\"_blank\">",
"        1763530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weintraub D, Siderowf AD, Potenza MN, et al, &ldquo;Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 2006, 63(7):969-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/16831966/pubmed\" id=\"16831966\" target=\"_blank\">",
"        16831966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zubenko GS, Barreira P, and Lipinski JF Jr, &ldquo;Development of Tolerance to the Therapeutic Effect of Amantadine on Akathisia,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1984, 4(4):218-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/46/13031/abstract-text/6470196/pubmed\" id=\"6470196\" target=\"_blank\">",
"        6470196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8508 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13031=[""].join("\n");
var outline_f12_46_13031=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132677\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132715\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132679\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132695\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132680\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132681\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671485\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132650\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132635\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132653\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132723\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132713\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132656\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132639\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298728\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132644\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132672\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132646\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132660\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132684\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11313487\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132659\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132648\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132661\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132638\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132655\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8508\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8508|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/53/3925?source=related_link\">",
"      Amantadine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/62/17383?source=related_link\">",
"      Amantadine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_46_13032="LIP with lymphoid hyperplasia";
var content_f12_46_13032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphocytic interstitial pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histopathology of&nbsp;lung biopsy showing lymphocytic interstitial pneumonia&nbsp;with lymphoid hyperplasia. A marked interstitial infiltrate of mononuclear cells and a germinal center are shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13032=[""].join("\n");
var outline_f12_46_13032=null;
var title_f12_46_13033="Clinical features of rheumatoid arthritis";
var content_f12_46_13033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features of rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/46/13033/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/46/13033/contributors\">",
"     PJW Venables, MA, MB BChir, MD, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/46/13033/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/46/13033/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/46/13033/contributors\">",
"     James R O'Dell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/46/13033/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/46/13033/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/46/13033/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disorder of unknown etiology that primarily involves joints. The arthritis is symmetrical and may be remitting, but, if uncontrolled, it may lead to destruction of joints due to erosion of cartilage and bone which leads to deformity. The disease usually progresses from the periphery to more proximal joints and, in patients who do not fully respond to treatment, results in significant locomotor disability within 10 to 20 years.",
"   </p>",
"   <p>",
"    Many of the clinical features that are discussed in this topic review are used in the clinical diagnosis of RA and also serve as classification criteria for RA. The latter are used to define patient populations with RA for clinical or other research purposes. The diagnosis and classification of RA are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a summary of characteristic clinical features, some of which are also useful for diagnostic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    classification purposes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Morning stiffness for at least one hour and present for at least six weeks",
"     </li>",
"     <li>",
"      Swelling of three or more joints for at least six weeks",
"     </li>",
"     <li>",
"      Swelling of wrist, metacarpophalangeal, or proximal interphalangeal joints for at least six weeks",
"     </li>",
"     <li>",
"      Symmetric joint swelling",
"     </li>",
"     <li>",
"      Hand x-ray changes typical of RA that include erosions or bony decalcification",
"     </li>",
"     <li>",
"      Rheumatoid subcutaneous nodules",
"     </li>",
"     <li>",
"      Rheumatoid factors or anti-citrullinated",
"      <span class=\"nowrap\">",
"       peptide/protein",
"      </span>",
"      antibodies",
"     </li>",
"     <li>",
"      Elevated acute phase reactants (erythrocyte sedimentation rate or C-reactive protein)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyarticular disease with a gradual onset, intermittent or migratory joint involvement, and a monoarticular onset are different types of clinical presentations of RA. In addition, extraarticular manifestations may be present.",
"   </p>",
"   <p>",
"    Patients need to be questioned regarding how the arthritis has affected their capacity to perform the activities of daily living (eg, walking, stairs, dressing, use of a toilet, getting up from a chair, opening jars, doors, typing), the type of job they have, and their ability to do their job.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Typical \"classic\" RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disease onset is usually insidious, with the predominant symptoms being pain, stiffness, and swelling of many joints [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/1\">",
"     1",
"    </a>",
"    ]. Typically, the metacarpophalangeal and proximal interphalangeal joints of the fingers, interphalangeal joints of the thumbs, the wrists, and metatarsophalangeal joints of the toes are sites of arthritis early in the disease. Other joints of the upper and lower limbs, such as the elbows, shoulders, ankles, and knees are also commonly affected [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Morning stiffness is a common feature of those with active RA; it has been defined as the following: \"slowness or difficulty moving the joints when getting out of bed or after staying in one position too long, which involves both sides of the body and gets better with movement\" [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Morning stiffness, or stiffness after any prolonged period of inactivity, is also seen in virtually all inflammatory arthropathies and myopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/5\">",
"     5",
"    </a>",
"    ]. However, morning stiffness lasting more than one hour reflects a severity of joint inflammation that rarely occurs in diseases other than RA.",
"   </p>",
"   <p>",
"    Up to one-third of patients have the acute onset of polyarthritis associated with prominent myalgia, fatigue, low grade fever, weight loss, and depression.",
"   </p>",
"   <p>",
"    Occasionally, the syndrome of polymyalgia rheumatica may be present. When this occurs in the absence of clinically detectable synovitis, the distinctive clinical features of RA may not develop until months or even years later. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polymyalgia rheumatica\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Palindromic rheumatism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of RA is episodic in a few patients, with one to several joint areas being affected sequentially for hours to days, with symptom free periods that may last from days to months; an episodic pattern referred to as \"palindromic rheumatism.\" Patients with palindromic rheumatism have similar predisposing genetic risk factors and exhibit a dose effect of carriage of certain HLA alleles, as do patients with a more typical persistent presentation of RA [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39593?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis\", section on 'Genetic susceptibility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The proportion of patients presenting with palindromic rheumatism who progress to develop RA or another well defined disease varies between studies. In one study of 60 patients with palindromic rheumatism followed over 20 years, 40 (67 percent) developed RA [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/7\">",
"     7",
"    </a>",
"    ]. In another study, among 147 such patients seen in a tertiary referral center, 41 were eventually diagnosed with RA (28 percent) and 4 with other disorders (3 with systemic lupus erythematosus and 1 with Beh&ccedil;et&rsquo;s disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, a majority of those with palindromic rheumatism also had anti-citrullinated",
"    <span class=\"nowrap\">",
"     peptide/protein",
"    </span>",
"    antibodies (ACPA), a serologic finding that is common in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/8\">",
"     8",
"    </a>",
"    ]. In another study, ACPA were positive in 83 percent of patients who progressed to definite RA [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Anti-citrullinated peptide antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of antimalarial drugs may reduce the risk of progression to RA. One retrospective study of 113 such patients found that those who received antimalarials were 20 percent less likely to develop a chronic rheumatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Monoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent single joint arthritis (monoarthritis), frequently of a large joint such as the knee, shoulder, hip, wrist, or ankle, may be the sole manifestation or may herald the onset of polyarticular disease. There may be a history of joint trauma as an apparent initiating event. The interval between monoarthritis and polyarthritis may extend from days to several weeks in patients whose disease progresses. Until polyarthritis develops, the approach to such patients is that for any patient with monoarticular arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=see_link\">",
"     \"Evaluation of the adult with monoarticular pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Extraarticular involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraarticular features of RA, including anemia, fatigue, subcutaneous (\"rheumatoid\") nodules, pleuropericarditis, neuropathy, episcleritis, scleritis, splenomegaly, Sj&ouml;gren's syndrome, vasculitis, and renal disease, may occur during the course of the disease These and other systemic and extraarticular manifestations are presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with extraarticular manifestations also have the classic joint symptoms of RA. Rarely, patients present with extraarticular disease in the absence of clinical arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a proportion of patients complain of persistent nonarticular symptoms, such as generalized aching, stiffness, bilateral carpal tunnel syndrome, loss of weight, depression, and fatigue (the last simulating chronic fatigue syndrome). This constellation of symptoms may antedate the onset of polyarthritis by many months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DISTRIBUTION OF JOINT INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA eventually affects the peripheral joints in almost all patients. Involvement of axial and central joints, such as the interfacetal and atlantoaxial joints of the neck, acromioclavicular [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/11\">",
"     11",
"    </a>",
"    ], sternoclavicular, temporomandibular, cricoarytenoid joints, and shoulders and hips is less common, occurring in 20 to 50 percent of patients.",
"   </p>",
"   <p>",
"    Symmetrical involvement of joints is a characteristic feature, although this may be less apparent early in the disease. The severity of joint disease and consequent deformity is sometimes notably asymmetrical, an observation that may be attributed to increased structural damage to joints related to unilateral overuse of a dominant limb, or joint protection of a limb resulting from neurologic disease.",
"   </p>",
"   <p>",
"    The pattern of joint involvement may also be diagnostically useful. As an example, involvement limited to the distal interphalangeal joints is usually due to osteoarthritis, whereas proximal interphalangeal involvement can reflect either RA or osteoarthritis. Squeeze tenderness at the MCP and MTP joints and palpable synovial thickening at these joints are characteristic of RA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA shows a marked variation of clinical expression in individual patients (",
"    <a class=\"graphic graphic_table graphicRef75843 \" href=\"UTD.htm?25/60/26571\">",
"     table 1",
"    </a>",
"    ). This difference may be apparent in the number and pattern of joint involvement. As an example, some patients may have mainly small joints or large joints affected. A given patient may also have only a few or almost all joints involved. Finally, extraarticular disease may be prominent in a subset of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Patterns of progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variation is also seen in the course of disease activity and the rapidity of structural damage to joints [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients show fluctuation of disease activity over periods lasting weeks to months. This corresponds to an increase or decrease in symptoms of arthritis, a pattern which may recur throughout the course of the disease.",
"     </li>",
"     <li>",
"      Disease activity may not abate in about 10 to 20 percent of cases.",
"     </li>",
"     <li>",
"      Remission has been reported in a small proportion of patients with a well established diagnosis of RA [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/13\">",
"       13",
"      </a>",
"      ]. In our experience, however, this is very rare without disease modifying antirheumatic drugs (DMARDs). As an example, among 191 patients treated with such drugs beginning within a year of disease onset, 48 (25 percent) met criteria for remission after three years of treatment, and 38 (20 percent) after five years of DMARD therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some clinical features that can be assessed early in the course of RA may be predictive of the likelihood of achieving a remission with DMARD treatment. Patients with less initial disease activity, less disability, lower levels of acute phase reactants, absence of RF and antibodies to citrullinated peptides (ACPA), and less radiographic joint damage when initially evaluated, are more likely to achieve a remission when treated with DMARDs within the first year of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Disease activity versus structural damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of disease activity is based upon the state of the underlying inflammatory response and may be distinguished from the destructive process that leads to irreversible damage of the joint (",
"    <a class=\"graphic graphic_table graphicRef76890 \" href=\"UTD.htm?8/11/8380\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disease activity can (and does) vary. This variation in part reflects the endogenous rhythms of the disease process but is mainly the result of therapeutic interventions. Thus, periods of spontaneous exacerbations and quiescence, characterized by an increase (a \"flare\") or decrease in symptoms, are modulated by both the beneficial effects of drug therapy and withdrawal of therapy due to loss of efficacy or side effects.",
"     </li>",
"     <li>",
"      In contrast, structural damage is cumulative and irreversible. The degree of damage is closely linked to inflammation and hence to disease activity, but is also associated with degeneration and repair [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/15\">",
"       15",
"      </a>",
"      ]. As structural damage progresses, the detection of variation in disease activity by clinical examination becomes increasingly difficult. At these later stages, symptoms and signs of inflammation, such as pain, stiffness, tenderness, swelling, and joint effusions, may be caused either by continuing rheumatoid disease or as a secondary result of mechanical and degenerative change.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, disease activity is absent; in this circumstance, the disease is said to be in remission. Attempts to define clinical remission for clinical trials and in clinical practice, in order to understand better the natural history of RA and the effects of therapy, have resulted in provisional definitions of remission by a joint effort of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. A complete lack of joint pain, swelling, and tenderness may be impossible to achieve in patients who have developed structural damage of the joints, despite actual remission in the rheumatoid disease process, and is not required by the",
"    <span class=\"nowrap\">",
"     ACR/EULAR",
"    </span>",
"    criteria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=see_link&amp;anchor=H7361200#H7361200\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\", section on 'Remission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The current",
"    <span class=\"nowrap\">",
"     ACR/EULAR",
"    </span>",
"    definitions of remission include use of either the Simplified Disease Activity Index (for clinical trials) or the Clinical Disease Activity Index (in clinical practice). Alternatively, the definition of remission for clinical trials can be met in patients with scores on the tender joint count, swollen joint count, CRP (in",
"    <span class=\"nowrap\">",
"     mg/dl),",
"    </span>",
"    and patient global assessment (0-10 scale) all &le;1. The CRP can be excluded in clinical practice.",
"   </p>",
"   <p>",
"    Achieving a clinical remission does not preclude the development of further erosive changes. This was illustrated in a retrospective study of 187 patients who were in remission for six months and whose clinical course and radiographic findings were subsequently followed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/18\">",
"     18",
"    </a>",
"    ]. A majority (52 percent) remained in remission during two years of follow-up. Despite inapparent clinically active disease, one new erosion in a previously unaffected joint appeared in 14 percent of these patients.",
"   </p>",
"   <p>",
"    Because the past remission criteria of the ACR included measures of fatigue and required at least two months of sustained response, they had not been applied widely in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/13\">",
"     13",
"    </a>",
"    ]. Measures using the Disease Activity Score (DAS &lt;1.6 or DAS28 &lt;2.4 or 2.6) to define remission were previously also proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PHYSICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key features of early rheumatoid inflammation are pain and swelling of the affected joints. Painful inflammation is demonstrated either by local tenderness from pressure applied on the joint or by pain on moving the joint. Swelling may be due to synovial hypertrophy or effusion. Synovial thickening is detected by a \"boggy\" feel to a swollen joint, and effusion by demonstrating fluctuation. Heat and redness (the other signs of Celsus) are not prominent features of RA, although an involved joint is often perceptibly warmer on careful examination. The characteristic joint deformities are late manifestations of disease that result from the physical stresses and local anatomy of involved joints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     The hands",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main signs of disease can often be found in the hands early in the course of RA [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/22\">",
"     22",
"    </a>",
"    ]. Symmetrical effusions and soft tissue swelling around the metacarpophalangeal joints and proximal interphalangeal joints typically occur, although distal interphalangeal involvement can be seen later in the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/23\">",
"     23",
"    </a>",
"    ]. These joints are tender to the touch and exhibit a restricted range of movement. Palmar erythema may be present (as with any peripheral arthritis).",
"   </p>",
"   <p>",
"    Occasionally, thickening of the flexor tendons can be detected by palpation of the palm; this finding is due to synovitis of the tendon sheaths (\"tenosynovitis\"). Nodules may form along the palmar tendon sheaths, resulting in the tendon sheath catching (or triggering) and in an inability to fully extend the finger. The nodules may cause tendon rupture, especially of the extensor pollicis longus (extensor of the DIP joint of the thumb).",
"   </p>",
"   <p>",
"    Other physical signs include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced grip strength can be a surprisingly sensitive indicator of early disease, as well as a useful parameter in the evaluation of disease activity and progression. However, the multiplicity of factors (joint pain, tendon involvement, nerve compression, and muscle wasting) that contribute to a weak grip makes this assessment rather nonspecific.",
"     </li>",
"     <li>",
"      The whole hand may be swollen in very acute RA, with pitting edema over the dorsum giving rise to the \"boxing glove\" appearance. The range of movement of involved joints is restricted, and loss of active flexion may be so severe that the patient is unable to oppose the finger tips to the palm.",
"     </li>",
"     <li>",
"      Between 1 and 5 percent of patients present with carpal tunnel syndrome. Affected patients develop dysesthesia and muscle weakness of the first three fingers and the radial side of the fourth finger. A positive Tinel's or Phalen's sign is usually present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=see_link\">",
"       \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The characteristic joint deformities appear in more established chronic RA. These findings include ulnar deviation or \"ulnar drift\" swan neck or Boutonniere deformities of the fingers (",
"    <a class=\"graphic graphic_picture graphicRef57439 graphicRef66140 \" href=\"UTD.htm?23/50/24357\">",
"     picture 1A-B",
"    </a>",
"    ), or the \"bow string\" sign (prominence of the tendons in the extensor compartment of the hand). Occasional patients present with extensor tendon rupture, most commonly affecting the thumb, little or ring fingers of either hand. The nails and fingertips should also be examined in every patient for evidence of digital infarcts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     The upper limb",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the upper extremity joints may be involved in RA. The wrist is probably the most common to be involved. Early in the disease there is a loss of extension. Late changes due to erosive damage lead to volar subluxation and radial drift of the carpus, resulting in increasing prominence of the ulnar styloid and lateral deviation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/24\">",
"     24",
"    </a>",
"    ]. Tendon rupture can also occur at the wrist.",
"   </p>",
"   <p>",
"    The elbow is frequently affected, with loss of extension (fixed flexion) both in early and late disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76905 \" href=\"UTD.htm?38/55/39806\">",
"     image 1",
"    </a>",
"    ). An effusion or synovitis may be detected as a bulge between the head of the radius and the olecranon. A compressive neuropathy of the ulnar nerve, with dysesthesias of the fourth and fifth fingers, can result from elbow synovitis. Olecranon bursitis is also common. Destruction of the joint may occur due to erosion of cartilage and bone.",
"   </p>",
"   <p>",
"    The elbow is the most common site for subcutaneous rheumatoid nodules. These should always be looked and felt for in view of their diagnostic and prognostic importance.",
"   </p>",
"   <p>",
"    The shoulder, being more proximal, tends to be involved later in the disease. As an example, one prospective study assessed shoulder involvement over time in 74 patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/25\">",
"     25",
"    </a>",
"    ]. At 15 years, 55 percent had developed radiographic evidence of erosive glenohumeral joint disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/25\">",
"     25",
"    </a>",
"    ]. The most common site for erosions was the superolateral aspect of the humerus.",
"   </p>",
"   <p>",
"    Disease in the glenohumeral joint leads to painful restriction of movement resembling a capsulitis, and can result in the development of a \"frozen\" shoulder. This will typically cause pain at night, when the patient lies on the affected shoulder. Rotator cuff injury is common. Effusions are relatively rare, but when they occur they may be detected in the anterior glenohumeral joint as a filling of the depression under the clavicle anterior to the head of the humerus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     The lower limb",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foot involvement is common in early disease, with a pattern which mirrors that occurring in the hand.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tenderness of the metatarsophalangeal joints may be marked, resulting in the tendency to bear weight on the heels and hyperextend the toes.",
"     </li>",
"     <li>",
"      Erosive damage results in lateral drift of the toes, and plantar subluxation of the metatarsal heads, resulting in \"cock-up\" deformities. The latter may be palpable as bony lumps on the sole with associated callosities.",
"     </li>",
"     <li>",
"      Involvement of the tarsus and the associated tendon sheaths is also common, leading to pain on inversion or eversion of the foot and diffuse edema and erythema over the dorsum of the foot.",
"     </li>",
"     <li>",
"      Heel pain may be associated with retrocalcaneal bursitis tarsal tunnel syndrome, caused by impingement of the posterior tibial nerve. Tarsal tunnel syndrome is also associated with paresthesiae of the toes and is important because it is readily diagnosed by ultrasound and treated by local injection or surgical release. Two rare but easily missed causes of heel pain are Achilles tendon rupture or calcaneal stress fracture [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Arthritis of the ankle can lead to a diffuse swelling around the tibiotalar joints which may be red and edematous. These findings may be wrongly attributed to fluid retention or an infective cellulitis of the skin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The knee manifests many changes in RA. Synovial thickening is easily detected at the knee, often extending around the patella. Effusion is a common feature of knee involvement and can be elicited by patellar tap. Restriction of movement, particularly flexion, is also a common physical finding. In addition, ligamentous laxity leading to deformities and quadriceps atrophy is frequently observed.",
"   </p>",
"   <p>",
"    The popliteal fossa should always be palpated for evidence of a popliteal (Baker's) cyst [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/28\">",
"     28",
"    </a>",
"    ]. Ruptured Baker's cysts extending down the calf are of clinical importance because they can resemble a deep vein thrombosis or acute thrombophlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/29\">",
"     29",
"    </a>",
"    ]. A history of arthritis, morning stiffness, lack of a palpable occluded venous cord, and edema below the posterior of the knee all suggest a Baker's cyst. Traditionally, a ruptured Baker's cyst is demonstrated by arthrography, though it can now be reliably demonstrated by ultrasonography or magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27016?source=see_link\">",
"     \"Popliteal (Baker's) cyst\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Erosion of the femoral condyles and tibial plateau can result in either genu varus or genu valgus.",
"   </p>",
"   <p>",
"    Involvement of the hips typically occurs only in well established disease. Hip disease is most frequently manifested as pain in the groin, thigh, low back, or referred to the knee on standing or movement. Restriction of movement, detected by \"log rolling the leg\" or rotation of the hip, also may be seen. Pain in the lateral thigh suggests trochanteric bursitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     The axial skeleton",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical spine joints are the most clinically important joints in the axial skeleton in RA and may cause pain and stiffness of the neck. Long standing disease may lead to instability and cause symptoms such as neck pain, stiffness, radicular pain, related to subluxation. If the subluxation is causing spinal cord compression, there may be signs of long tract involvement such as hyperreflexia or up going toes on Babinski testing. The clinical manifestations of cervical spine subluxation and the approach to diagnosis and management are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=see_link\">",
"     \"Cervical subluxation in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cricoarytenoid joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly 30 percent of patients with RA have involvement of the cricoarytenoid joint; symptoms may include hoarseness and an inspiratory stridor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1597589\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of abnormalities are present in the blood and synovial fluid of patients with RA. These include changes reflecting systemic and intraarticular inflammation, and the autoimmune features of the disorder, including the presence of rheumatoid factors and anti-citrullinated peptide antibodies.",
"   </p>",
"   <p>",
"    Synovial fluid examination typically reveals an inflammatory effusion, with a leukocyte count typically between 1500 and",
"    <span class=\"nowrap\">",
"     25,000/cubic",
"    </span>",
"    mm characterized by a predominance of polymorphonuclear cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/31\">",
"     31",
"    </a>",
"    ]. Cell counts in excess of 25,000 may occur in very active disease, but levels over 25,000 should alert the clinician to the increased possibility of coexisting infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Additional findings in RA synovial fluid are low glucose, low C3 and C4 complement levels, and protein levels approaching those in serum, but these tests are generally not obtained in clinical practice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"     \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link&amp;anchor=H8594869#H8594869\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\", section on 'Evaluation for suspected RA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other laboratory features of RA are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=see_link\">",
"     \"Hematologic manifestations of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1597644\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with RA develop joint space narrowing and bony erosions, which are best observed in radiographs of the hands and feet. These may already be present when first seen by a clinician but more usually become evident over time with ongoing synovitis beyond the first few months of disease. Erosions of cartilage and bone are among the cardinal features of RA. However, they can also occur in some other forms of inflammatory and gouty arthropathy and are, therefore, not diagnostic of RA in and of themselves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link&amp;anchor=H16#H16\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) studies and ultrasonography are more sensitive than radiography for the detection of changes resulting from synovitis, but additional research is ongoing to determine the prognostic importance of changes observed with these studies that are not evident radiographically.",
"   </p>",
"   <p>",
"    With extreme destruction, the severity of erosions may reach a level beyond which further progression cannot be assessed radiographically, despite the presence of ongoing joint damage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1598951\">",
"    <span class=\"h2\">",
"     Plain film radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs are often normal early in disease, and the early changes evident on plain films may include only soft tissue swelling and periarticular osteopenia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83905 graphicRef85825 graphicRef85829 \" href=\"UTD.htm?21/44/22217\">",
"     image 2A-C",
"    </a>",
"    ). To be detected by plain radiography, erosions must have eroded through the cortex of the bone around the margins of the joint. Erosions in the metacarpophalangeal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85826 graphicRef85827 \" href=\"UTD.htm?9/33/9753\">",
"     image 3A-B",
"    </a>",
"    ) and proximal interphalangeal joints (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85824 graphicRef85836 \" href=\"UTD.htm?30/4/30792\">",
"     image 4A-B",
"    </a>",
"    ) can be identified by plain radiography in 15 to 30 percent of patients in the first year of the disease. By the end of the second year of disease in patients who do not respond to therapy, the cumulative incidence of erosions is 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In some patients, erosions occur first in the ulnar styloid (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85828 graphicRef85830 \" href=\"UTD.htm?39/57/40855\">",
"     image 5A-B",
"    </a>",
"    ) or MTP joints (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85831 graphicRef85820 \" href=\"UTD.htm?0/55/889\">",
"     image 6A-B",
"    </a>",
"    ). Joint space narrowing may also be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1598958\">",
"    <span class=\"h2\">",
"     MR imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is a more sensitive technique than plain radiography for identifying bone erosions. When radiography and MRI were compared in a group of 55 patients with early arthritis, MRI identified seven times as many erosions in the metacarpophalangeal and proximal interphalangeal joints than plain radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/37\">",
"     37",
"    </a>",
"    ]. However, the clinical significance of erosions only detected by MRI awaits elucidation.",
"   </p>",
"   <p>",
"    MRI also may detect bone erosions earlier in the course of the disease than is possible with plain films [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/38\">",
"     38",
"    </a>",
"    ]. As an example, approximately 45 percent of patients with symptoms for only four months were found to have erosions detected by this method [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/39\">",
"     39",
"    </a>",
"    ]. Decreased signal from the bone marrow on T1-weighted images and enhancement of the marrow with gadolinium administration is interpreted as bone marrow edema. The presence of marrow edema on MRI is predictive of later development of erosive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/40\">",
"     40",
"    </a>",
"    ]. A similarly increased sensitivity of MRI has also been noted for early RA of the forefoot [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also possible to identify and estimate the quantity of hypertrophic synovial tissue using MRI. The presence of MRI-detected synovial proliferation correlates with the later development of bone erosions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/42\">",
"     42",
"    </a>",
"    ]. Use of this imaging technique outside of research settings may be hastened by the development of MRI scanners that are designed specifically for imaging the extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1598965\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is another alternative for estimating the degree of inflammation and the volume of inflamed tissue. Direct comparison of color Doppler ultrasonography and contrast enhanced MRI in one study of 29 patients demonstrated agreement regarding the presence or absence of inflammation between the two techniques in 75 percent of the joints of the hands and wrists [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/45\">",
"     45",
"    </a>",
"    ]. Both imaging modalities found features of inflammation in joints that were neither tender nor swollen on physical examination. The clinical importance of these findings remains to be determined. Ultrasonography can also be used to assess the MTP joints, which may become affected early in the course of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13033/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=see_link\">",
"       \"Patient information: Hand pain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"       \"Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281164264\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The onset of rheumatoid arthritis (RA) is usually insidious, with the predominant symptoms being pain, stiffness, and swelling of many joints. Onset may occasionally be intermittent or with migratory joint involvement, or onset may be monoarticular. RA may adversely affect a patient&rsquo;s capacity to perform the activities of daily living. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Typical \"classic\" RA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Palindromic rheumatism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Monoarthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extraarticular features of RA, including anemia, fatigue, subcutaneous (\"rheumatoid\") nodules, pleuropericarditis, neuropathy, episcleritis, scleritis, splenomegaly, Sj&ouml;gren's syndrome, vasculitis, and renal disease, may occur during the course of the disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Extraarticular involvement'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link\">",
"       \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      RA eventually affects the peripheral joints in almost all patients. Involvement of axial and central joints is less common, occurring in 20 to 50 percent of patients. Symmetrical joint involvement is characteristic, although this may be less apparent early in the disease. The pattern of joint involvement may also be diagnostically useful. Squeeze tenderness at the MCP and MTP joints and palpable synovial thickening at these joints are characteristic of RA. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Distribution of joint involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      RA shows a marked variation of clinical expression in individual patients (",
"      <a class=\"graphic graphic_table graphicRef75843 \" href=\"UTD.htm?25/60/26571\">",
"       table 1",
"      </a>",
"      ). This difference may be apparent in the number and pattern of joint involvement and whether extraarticular disease is prominent. Variation is also seen in the course of disease activity and the rapidity of structural damage to joints. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical course'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Patterns of progression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The concept of disease activity is based upon the state of the underlying inflammatory response, and may be distinguished from the destructive process that leads to irreversible damage of the joint (",
"      <a class=\"graphic graphic_table graphicRef76890 \" href=\"UTD.htm?8/11/8380\">",
"       table 2",
"      </a>",
"      ). Rarely, disease activity is absent; in this circumstance, the disease is said to be in remission. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Disease activity versus structural damage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Remission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The key features of early rheumatoid inflammation are pain and swelling of the affected joints. Painful inflammation is demonstrated either by local tenderness from pressure applied on the joint or by pain on moving the joint. Swelling may be due to synovial hypertrophy or effusion. Synovial thickening is detected by a \"boggy\" feel to a swollen joint, and effusion by demonstrating fluctuation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Physical findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'The hands'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'The lower limb'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'The axial skeleton'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Cricoarytenoid joint'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of abnormalities are present in the blood and synovial fluid of patients with RA. These include changes reflecting systemic and intraarticular inflammation, and the autoimmune features of the disorder, including the presence of rheumatoid factors and anti-citrullinated peptide antibodies. (See",
"      <a class=\"local\" href=\"#H1597589\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with RA develop joint space narrowing and bony erosions, which are best observed in radiographs of the hands and feet. These may already be present when first seen by a physician but more usually become evident over time with ongoing synovitis beyond the first few months of disease. (See",
"      <a class=\"local\" href=\"#H1597644\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/1\">",
"      Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/2\">",
"      Fleming A, Crown JM, Corbett M. Early rheumatoid disease. I. Onset. Ann Rheum Dis 1976; 35:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/3\">",
"      Jacoby RK, Jayson MI, Cosh JA. Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up. Br Med J 1973; 2:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/4\">",
"      Lineker S, Badley E, Charles C, et al. Defining morning stiffness in rheumatoid arthritis. J Rheumatol 1999; 26:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/5\">",
"      Edworthy SM. Morning stiffness: sharpening an old saw? J Rheumatol 1999; 26:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/6\">",
"      Maksymowych WP, Suarez-Almazor ME, Buenviaje H, et al. HLA and cytokine gene polymorphisms in relation to occurrence of palindromic rheumatism and its progression to rheumatoid arthritis. J Rheumatol 2002; 29:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/7\">",
"      Koskinen E, Hannonen P, Sokka T. Palindromic rheumatism: longterm outcomes of 60 patients diagnosed in 1967-84. J Rheumatol 2009; 36:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/8\">",
"      Salvador G, Gomez A, Vinas O, et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? Rheumatology (Oxford) 2003; 42:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/9\">",
"      Russell AS, Devani A, Maksymowych WP. The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. J Rheumatol 2006; 33:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/10\">",
"      Gonzalez-Lopez L, Gamez-Nava JI, Jhangri G, et al. Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials. J Rheumatol 2000; 27:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/11\">",
"      Lehtinen JT, Kaarela K, Belt EA, et al. Incidence of acromioclavicular joint involvement in rheumatoid arthritis: a 15 year endpoint study. J Rheumatol 1999; 26:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/12\">",
"      Masi AT. Articular patterns in the early course of rheumatoid arthritis. Am J Med 1983; 75:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/13\">",
"      Pinals RS, Baum J, Bland J, et al. Preliminary criteria for clinical remission in rheumatoid arthritis. Bull Rheum Dis 1982; 32:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/14\">",
"      Gossec L, Dougados M, Goupille P, et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 2004; 63:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/15\">",
"      Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 1998; 41:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/16\">",
"      Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/17\">",
"      Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011; 70:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/18\">",
"      Molenaar ET, Voskuyl AE, Dinant HJ, et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004; 50:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/19\">",
"      van Gestel AM, Anderson JJ, van Riel PL, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 1999; 26:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/20\">",
"      Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005; 52:2625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/21\">",
"      van der Heijde D, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005; 64:1582.",
"     </a>",
"    </li>",
"    <li>",
"     Rheumatoid arthritis &mdash; contemporary patient management series, 2nd, Gordon, DA (Eds), Medical Examination Publishing, New York 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/23\">",
"      Jacob J, Sartoris D, Kursunoglu S, et al. Distal interphalangeal joint involvement in rheumatoid arthritis. Arthritis Rheum 1986; 29:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/24\">",
"      Hastings DE, Evans JA. Rheumatoid wrist deformities and their relation to ulnar drift. J Bone Joint Surg Am 1975; 57:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/25\">",
"      Lehtinen JT, Kaarela K, Belt EA, et al. Incidence of glenohumeral joint involvement in seropositive rheumatoid arthritis. A 15 year endpoint study. J Rheumatol 2000; 27:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/26\">",
"      Rask MR. Achilles tendon rupture owing to rheumatoid disease. Case report with a nine-year follow-up. JAMA 1978; 239:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/27\">",
"      Semba CP, Mitchell MJ, Sartoris DJ, Resnick D. Multiple stress fractures in the hindfoot in rheumatoid arthritis. J Rheumatol 1989; 16:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/28\">",
"      Gerber NJ, Dixon AS. Synovial cysts and juxta-articular bone cysts. Semin Arthritis Rheum 1974; 3:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/29\">",
"      Kraag G, Thevathasan EM, Gordon DA, Walker IH. The hemorrhagic crescent sign of acute synovial rupture. Ann Intern Med 1976; 85:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/30\">",
"      Torreggiani WC, Al-Ismail K, Munk PL, et al. The imaging spectrum of Baker's (Popliteal) cysts. Clin Radiol 2002; 57:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/31\">",
"      Dougados M. Synovial fluid cell analysis. Baillieres Clin Rheumatol 1996; 10:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/32\">",
"      Krey PR, Bailen DA. Synovial fluid leukocytosis. A study of extremes. Am J Med 1979; 67:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/33\">",
"      Kortekangas P, Aro HT, Tuominen J, Toivanen A. Synovial fluid leukocytosis in bacterial arthritis vs. reactive arthritis and rheumatoid arthritis in the adult knee. Scand J Rheumatol 1992; 21:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/34\">",
"      Kuper IH, van Leeuwen MA, van Riel PL, et al. Influence of a ceiling effect on the assessment of radiographic progression in rheumatoid arthritis during the first 6 years of disease. J Rheumatol 1999; 26:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/35\">",
"      van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/36\">",
"      Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/37\">",
"      Klarlund M, Ostergaard M, Jensen KE, et al. Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one year follow up of patients with early arthritis. The TIRA Group. Ann Rheum Dis 2000; 59:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/38\">",
"      McQueen FM. The use of MRI in early RA. Rheumatology (Oxford) 2008; 47:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/39\">",
"      McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998; 57:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/40\">",
"      McQueen FM, Benton N, Perry D, et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/41\">",
"      Ostendorf B, Scherer A, M&ouml;dder U, Schneider M. Diagnostic value of magnetic resonance imaging of the forefeet in early rheumatoid arthritis when findings on imaging of the metacarpophalangeal joints of the hands remain normal. Arthritis Rheum 2004; 50:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/42\">",
"      McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis 1999; 58:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/43\">",
"      Ejbjerg BJ, Narvestad E, Jacobsen S, et al. Optimised, low cost, low field dedicated extremity MRI is highly specific and sensitive for synovitis and bone erosions in rheumatoid arthritis wrist and finger joints: comparison with conventional high field MRI and radiography. Ann Rheum Dis 2005; 64:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/44\">",
"      Naraghi AM, White LM, Patel C, et al. Comparison of 1.0-T extremity MR and 1.5-T conventional high-field-Strength MR in patients with rheumatoid arthritis. Radiology 2009; 251:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/45\">",
"      Terslev L, Torp-Pedersen S, Savnik A, et al. Doppler ultrasound and magnetic resonance imaging of synovial inflammation of the hand in rheumatoid arthritis: a comparative study. Arthritis Rheum 2003; 48:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13033/abstract/46\">",
"      Szkudlarek M, Narvestad E, Klarlund M, et al. Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis: comparison with magnetic resonance imaging, conventional radiography, and clinical examination. Arthritis Rheum 2004; 50:2103.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7502 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13033=[""].join("\n");
var outline_f12_46_13033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H281164264\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Typical \"classic\" RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Palindromic rheumatism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Monoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Extraarticular involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DISTRIBUTION OF JOINT INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Patterns of progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Disease activity versus structural damage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Remission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PHYSICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      The hands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      The upper limb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      The lower limb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      The axial skeleton",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cricoarytenoid joint",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1597589\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1597644\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1598951\">",
"      Plain film radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1598958\">",
"      MR imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1598965\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281164264\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7502\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7502|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/55/39806\" title=\"diagnostic image 1\">",
"      RA of the elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/59/33714\" title=\"diagnostic image 2A\">",
"      RA PIP soft tissue swelling x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/0/25601\" title=\"diagnostic image 2B\">",
"      RA MCP osteopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/4/4161\" title=\"diagnostic image 2C\">",
"      RA wrist osteopenia x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/32/515\" title=\"diagnostic image 3A\">",
"      RA MCP mild erosion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/2/35877\" title=\"diagnostic image 3B\">",
"      Normal left hand x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/33/31250\" title=\"diagnostic image 4A\">",
"      RA PIP erosions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/19/31028\" title=\"diagnostic image 4B\">",
"      Normal right hand x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/6/9314\" title=\"diagnostic image 5A\">",
"      RA ulnar styloid erosion x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/19/8499\" title=\"diagnostic image 5B\">",
"      Normal wrist x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/13/212\" title=\"diagnostic image 6A\">",
"      RA MTP erosions x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/50/16164\" title=\"diagnostic image 6B\">",
"      X-ray left foot normal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7502|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/15/21746\" title=\"picture 1A\">",
"      RA hand 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/2/3119\" title=\"picture 1B\">",
"      RA hand 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7502|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/60/26571\" title=\"table 1\">",
"      History and prognosis of RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/11/8380\" title=\"table 2\">",
"      Assessment of activity RA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=related_link\">",
"      Assessment of rheumatoid arthritis activity in clinical trials and clinical practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=related_link\">",
"      Cervical subluxation in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=related_link\">",
"      Clinical manifestations and diagnosis of polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=related_link\">",
"      Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39593?source=related_link\">",
"      Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=related_link\">",
"      Evaluation of the adult with monoarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=related_link\">",
"      Hematologic manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=related_link\">",
"      Patient information: Hand pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27016?source=related_link\">",
"      Popliteal (Baker's) cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=related_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_46_13034="Physiology and clinical use of melatonin";
var content_f12_46_13034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiology and clinical use of melatonin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/46/13034/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/46/13034/contributors\">",
"     Richard Wurtman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/46/13034/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/46/13034/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/46/13034/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/46/13034/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/46/13034/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melatonin is a hormone produced in the pineal gland from the amino acid tryptophan and secreted into the blood and cerebrospinal fluid. It conveys signals to distant organs, principally the brain, and affects the synthesis of second messengers and, ultimately, sleep and circadian rhythms. However, unlike most other hormones, melatonin&rsquo;s use is not regulated in many countries. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Regulatory issues'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic review will discuss melatonin's history, current knowledge of its synthesis and metabolism, the physiologic regulation of plasma melatonin concentrations, the known effects of endogenous and exogenous (oral) melatonin in humans, and the melatonin analogs currently approved for use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human pineal gland is an important structure that transmits signals to the brain and other organs by secreting its unique hormone, melatonin. However this concept is only a few decades old. For most of the twentieth century, the pineal was generally dismissed as a \"vestige,\" a \"third eye\" in certain lower vertebrates, the cells of which, in humans, died and became calcified early in life. Tumors of the pineal gland were known sometimes to be associated with a reproductive disorder, precocious puberty, especially in boys, and some scientists attributed this phenomenon to the destruction of functioning pineal tissue. However, the majority concluded that the accelerated sexual maturation was simply a nonspecific consequence of increased intracranial pressure.",
"   </p>",
"   <p>",
"    In 1917, the modern history of the pineal gland began with the discovery that cow pineals contained a compound that could lighten the skin of frogs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/1\">",
"     1",
"    </a>",
"    ]. The physiological significance of this relationship seemed obscure, as bovine pineal extracts had no effect on pigmentation in bovines (nor humans), and frog pineals lacked detectable skin-lightening ability. However the finding did indicate that the pineal contained a compound with at least some biological activity, and it provided a way for identifying the active compound, using assays based on the ability of sequentially-purified pineal extracts to aggregate the melanin granules in the frog's pigment cells. In 1958, one study identified that compound's chemical structure as 5-methoxy-N-acetyltryptamine and named it melatonin&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the prior decade, scientists had made four seemingly unrelated discoveries that became coherent, once melatonin was identified and could be tested. These included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The demonstration that surgical removal of the rat's pineal accelerated the growth of the ovaries, while administration of bovine pineal extracts had the opposite effect [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The observation that housing rats in a continuously-lit environment decreased the weights of their pineals [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The discovery that, though the pineal gland originates embryologically as part of the brain, it loses most or all of its CNS connections by birth, and instead receives its innervation from peripheral sympathetic nerves [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The demonstration that pinealectomy or prolonged light exposure, or both procedures, accelerate the growth of the ovaries to an equal extent, and that the effects of the two treatments are blocked by giving the animals pineal extracts [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Between 1963 and 1964, it was shown that melatonin was a hormone in rats, that it was the gonad-inhibiting substance previously described in pineal extracts, and that its synthesis in the pineal gland was suppressed when rats were exposed continuously to light, the light acting not directly, as on a \"third eye,\" but indirectly, via the animal's eyes and sympathetic nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The chemical that mediates the sympathetic nervous signals was subsequently shown to be norepinephrine, which stimulates beta-receptors and thereby increases pineal production of cyclic-AMP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. The rates at which the rats&rsquo; pineal synthesizes serotonin and melatonin were soon shown to vary with circadian rhythms, and the melatonin rhythm was ultimately found to be generated by intrinsic circadian signals emanating from the suprachiasmatic nucleus of the brain, which were controlled primarily by the light-dark cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, in 1975, it was discovered that melatonin production in humans, like that in all other mammals studied, exhibits a pronounced circadian rhythm such that nocturnal plasma melatonin concentrations are at least 10-fold higher than daytime concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/16\">",
"     16",
"    </a>",
"    ]. Moreover, this rhythm is truly circadian, and not simply a response to the environmental light-dark cycle. This was illustrated in a study of subjects who underwent a 12-hour phase shift in the light-dark cycle (dark between 11 am and 7 pm instead of the customary 11 pm to 7 am); five to seven days were needed for their melatonin rhythms to re-entrain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The view thus became canonized that the pineal is a \"neuroendocrine transducer\" that tells all mammals when it is dark outside by raising their plasma melatonin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/18\">",
"     18",
"    </a>",
"    ]. The uses to which the body puts this information vary considerably among species. In diurnal (but not nocturnal) animals, melatonin promotes sleep onset and maintenance. In animals that breed seasonally, melatonin influences the choice of breeding season (ie, Spring or Fall). In humans, although there is evidence that endogenous melatonin may have an effect on puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/19\">",
"     19",
"    </a>",
"    ], no reproductive effects of exogenous melatonin have been clearly demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Much subsequent pineal research has concerned the human brain's responses to melatonin rhythms. The most compelling evidence now available supports two roles for melatonin in humans: the involvement of nocturnal melatonin secretion in initiating and maintaining sleep and control by the",
"    <span class=\"nowrap\">",
"     day/night",
"    </span>",
"    melatonin rhythm of the timing of other 24-hour rhythms. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Circadian rhythm'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Melatonin's effect on sleep underlies most of its current use as a drug and the development of melatonin analogs as new drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Some additional possible benefits of melatonin supplementation or melatonin analogs have been proposed (eg, as an antioxidant, or to slow aging, or to suppress cancer growth, or to treat depression). However, compelling evidence to support these effects is limited.",
"   </p>",
"   <p>",
"    Evidence is even more limited for labeling melatonin as a \"dietary supplement\" (which is what it is considered to be by the United States Food and Drug Administration). For melatonin to earn this appellation, it would have to be shown that at least some of the melatonin molecules in human plasma derive from food sources, and that \"supplementary\" exogenous melatonin simply adds to what the foods provide. But there is no satisfactory evidence based on contemporary analytic techniques that any available foods contain more than trace amounts of melatonin, and no evidence at all that eating any food elevates human plasma melatonin concentrations. Despite its lack of overt toxicity, melatonin is a",
"    <strong>",
"     hormone",
"    </strong>",
"    , and should be labeled and regulated as such.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Regulatory issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melatonin products are regulated differently in many countries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, melatonin falls under the Food and Drug Administration's Dietary Health and Education Act as a \"dietary supplement.\" It can be purchased in any dose without a prescription.",
"     </li>",
"     <li>",
"      In the European Union, melatonin has been evaluated by an official regulatory agency, the European Food Safety Authority (EFSA), for use in reducing sleep latency, the time it takes for normal sleepers or people with insomnia to fall asleep (at bedtime or after a nocturnal awakening) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/24\">",
"       24",
"      </a>",
"      ]. Based on the evidence provided in all three of the statistically-valid published meta-analyses [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/25-27\">",
"       25-27",
"      </a>",
"      ], the agency concluded that there exists &ldquo;a cause and effect relationship between the consumption of melatonin and a reduction of sleep onset latency&rdquo; and that &ldquo;in order to obtain the claimed effect, 1 mg of melatonin should be consumed close to bedtime&rdquo; [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Canada, melatonin is included in the Natural Health Products Directorate of Health Canada and is available for sale, once preparations meet the licensing, manufacturing, labeling, and safety standards.",
"     </li>",
"     <li>",
"      In Australia, melatonin is an unregistered product under the Therapeutic Goods Administration. With a prescription, it can be imported for use under the Personal Import Scheme.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note is that in situations where the sale of melatonin is not regulated, enormous doses can be sold, and preparations may contain additives that have their own pharmacological actions and potential side effects. Occasional claims to the contrary notwithstanding, apparently all of the melatonin sold in the United States is of synthetic origin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MELATONIN SYNTHESIS AND METABOLISM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all of the melatonin formed in mammals is synthesized within the pineal gland from the essential amino acid tryptophan (",
"    <a class=\"graphic graphic_figure graphicRef77541 \" href=\"UTD.htm?41/7/42110\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/10\">",
"     10",
"    </a>",
"    ]. Small amounts of melatonin have sometimes also been described in the retina, Harderian gland, and enterochromaffin cells of the gut; however, there is little evidence based on specific GCMS (gas chromatography mass spectroscopy) or bioassay methods that this putative extrapineal melatonin actually represents the authentic hormone. Moreover, plasma melatonin and its circadian rhythm largely or completely disappear among pinealectomized animals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/28\">",
"     28",
"    </a>",
"    ] or human subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/29\">",
"     29",
"    </a>",
"    ]. Since the pineal lies outside the blood-brain barrier, tryptophan's uptake by the pineal, in contrast to its uptake into the brain, is not subject to competition from other circulating neutral amino acids, and thus is unaffected by diet composition. The tryptophan is first 5-hydroxylated (by the enzyme tryptophan hydroxylase) and then decarboxylated (by the enzyme aromatic L-amino acid decarboxylase) to form 5-hydroxytryptamine, or serotonin (",
"    <a class=\"graphic graphic_figure graphicRef77541 \" href=\"UTD.htm?41/7/42110\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During daylight hours, the serotonin in pinealocytes tends to be stored and unavailable to enzymes (monoamine oxidase and the melatonin-forming enzymes) that would otherwise act on it. With the onset of darkness, postganglionic sympathetic outflow to the pineal increases and the consequent release of norepinephrine onto pinealocytes causes stored serotonin to become accessible for intracellular metabolism. At the same time, the norepinephrine activates the enzymes, especially serotonin-N-acetyltransferase (SNAT) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/30\">",
"     30",
"    </a>",
"    ], but also hydroxyindole-O-methyltransferase (HIOMT) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/8,31\">",
"     8,31",
"    </a>",
"    ], that convert serotonin to melatonin. Consequently, pineal melatonin levels rise many-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/14\">",
"     14",
"    </a>",
"    ]. Pineal levels of the corresponding deaminated and O-methylated metabolite of serotonin, 5-methoxytryptophol, also rise [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/32\">",
"     32",
"    </a>",
"    ], even though formation of this compound is independent of SNAT. This suggests that the daily rhythm in pineal SNAT activity is not the cause of the rhythm in melatonin synthesis, as has sometimes been proposed.",
"   </p>",
"   <p>",
"    The melatonin then diffuses out of the pineal gland and into the blood stream and cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/33\">",
"     33",
"    </a>",
"    ], rapidly raising its plasma concentrations from about 2 to 10",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    to 100 to 200",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/16\">",
"     16",
"    </a>",
"    ]. Melatonin is highly lipid-soluble because both of the ionizable groups in serotonin, the hydroxyl and the amine, have been blocked by its O-methylation and N-acetylation. Thus, it diffuses freely across cell membranes, including those of the blood-brain barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/34\">",
"     34",
"    </a>",
"    ], and travels in the blood largely bound to albumin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the melatonin in the circulation is inactivated in the liver, where it is first oxidized to 6-OH-melatonin by a P450-dependent microsomal oxidase and then largely conjugated to sulfate or glucuronide before being excreted into the urine or feces [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/36\">",
"     36",
"    </a>",
"    ]. About 2 to 3 percent of the circulating melatonin is excreted unchanged into the urine or the saliva, enabling measurements of urinary or salivary melatonin to be used as rough estimates of plasma melatonin concentrations. Salivary melatonin levels apparently correspond to those of the 25 to 30 percent of blood melatonin that is not bound to albumin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Melatonin receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies using radioactively-labeled melatonin have identified three probable melatonin receptors, two of which have been cloned using human sources [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/37\">",
"     37",
"    </a>",
"    ]. These macromolecules are concentrated, respectively, within the suprachiasmatic nucleus of the hypothalamus, the pars tuberalis of the pituitary, and cardiac blood vessels (MT1); the retina and hippocampus (MT2); and in kidney, brain, and various peripheral organs (MT3). Their affinities for melatonin are enhanced in the presence of several G-proteins.",
"   </p>",
"   <p>",
"    Activation of the MT1 and MT2 receptors by melatonin suppresses cAMP production, but can also stimulate phospholipase C and various ion channels. The MT2 receptor also mediates melatonin's ability to inhibit hippocampal long-term potentiation in brain slices [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/38\">",
"     38",
"    </a>",
"    ]. The MT3 site shares 95 percent homology with a detoxifying enzyme, quinone reductase 2; its effects on specific signal transduction pathways await identification. Because of melatonin's unusual lipid-solubility, its receptors could be located intracellularly, in contrast to the plasma membrane receptors characteristic of neurotransmitters; indeed, a nuclear binding site has been identified. The MT1 receptors in the SCN allow melatonin to inhibit the firing of SCN neurons during the nighttime, an action that might contribute to melatonin's sleep-promoting effects. The SCN's MT2 receptors apparently mediate melatonin's effects on the SCN's own circadian rhythms.",
"   </p>",
"   <p>",
"    Melatonin's MT1 and MT2 receptors are highly susceptible to \"desensitization,\" their activity decreasing markedly after exposure to supranormal concentrations of the hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. This bears on the prolonged use of high melatonin doses to promote sleep, particularly in older people with difficulty remaining asleep during the night who might inadvertently purchase excessively large doses of the hormone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Circadian rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all mammals examined thus far, melatonin secretion manifests a similar circadian rhythm, with plasma and urine concentrations low during daylight, ascending after the onset of darkness, peaking in the middle of the night between 11 pm and 3 am, and then falling sharply before the time of light onset [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/16\">",
"     16",
"    </a>",
"    ]. It should be noted that high nocturnal plasma melatonin concentrations are characteristic of both diurnally-active species (like humans), in which the high levels promote sleep onset and maintenance, and nocturnally-active ones (like rats), in which melatonin has no obvious relationship to sleep.",
"   </p>",
"   <p>",
"    While this rhythm normally is tightly entrained to the environmental light cycle, it does persist when people are placed for a few days in a dark room [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/41\">",
"     41",
"    </a>",
"    ] and, as described above, does not immediately phase-shift when the light schedule is altered [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/17\">",
"     17",
"    </a>",
"    ], indicating that it is not simply generated by the light-dark cycle but also by cyclic endogenous signals, probably arising in the SCN. Signals originating in the retina or the SCN reach the pineal via a retinohypothalamic tract, the superior cervical ganglia, and postganglionic sympathetic fibers that re-enter the cranial cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/9,42\">",
"     9,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In certain fish, birds, and reptiles, pineal glands also contain true photoreceptors, and denervated (or even cultured) glands can sustain circadian rhythms in melatonin synthesis which can be entrained by the light-dark cycle. In contrast, light has no known direct effects on pineal melatonin synthesis in humans and other mammals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PLASMA MELATONIN CONCENTRATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma melatonin concentration reflects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The amount secreted by the pineal gland (and, conceivably, the other organs described above)",
"     </li>",
"     <li>",
"      The influx of melatonin into tissues when its plasma concentrations are high and efflux from them when plasma concentrations are low",
"     </li>",
"     <li>",
"      Its destruction in the liver",
"     </li>",
"     <li>",
"      Its secretion into such body fluids as urine and saliva",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Usually, the principal factor affecting plasma melatonin concentration is its rate of secretion, which varies with the circadian rhythm and with age (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Circadian rhythm'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Age'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Effect of diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Now, at a time when melatonin is also generally available as a dietary supplement, plasma concentrations can also reflect consumption of the exogenous compound. Available evidence does not support the view that humans derive any of their plasma melatonin from foods. Several laboratories have described a compound in dietary fruits or vegetables (eg, tomato [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]) that they concluded was melatonin. But in only one of these studies was the identity of the melatonin unambiguously confirmed by gas chromatography-mass spectrometry, and in that study the melatonin concentrations were very low (&lt;20",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    of fruit) and were thought to represent contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/45\">",
"     45",
"    </a>",
"    ]. Of perhaps greater relevance, it has never been reported that feeding any amount of any food to humans can raise plasma melatonin concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melatonin secretion by the human pineal varies markedly with age. Melatonin secretion starts during the third or fourth months of life, coincident with the consolidation of sleeping at nighttime [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/46\">",
"     46",
"    </a>",
"    ]. It then increases rapidly, causing nocturnal melatonin concentrations to peak at ages one to three years, then decline slightly to a plateau that persists throughout early adulthood (",
"    <a class=\"graphic graphic_figure graphicRef78560 \" href=\"UTD.htm?4/23/4478\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Nocturnal melatonin secretion then starts a marked continuing decline in most people, with peak nocturnal concentrations in 70 year olds being only a quarter or less of what they are in young adults (",
"    <a class=\"graphic graphic_figure graphicRef78560 \" href=\"UTD.htm?4/23/4478\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/19,47\">",
"     19,47",
"    </a>",
"    ]. This decline may reflect the progressive, age-related calcification of the pineal gland and its resulting loss of secretory tissue. Obviously, one strategy in using supplemental melatonin is to administer it to older people in doses just sufficient to compensate for this age-related decline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effects of drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturnal melatonin concentrations can also be affected by drugs that interfere with the transmission of neurotransmitter signals to pineal cells (like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , a beta-blocking agent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/48\">",
"     48",
"    </a>",
"    ]) or those that inhibit melatonin's metabolism (like 8-methoxypsoralen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/49\">",
"     49",
"    </a>",
"    ]), and by a few drugs that lack clear links to melatonin's synthesis or metabolism (eg, caffeine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/50\">",
"     50",
"    </a>",
"    ], ethanol [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Nocturnal melatonin secretion is also suppressed by exposure to environmental lighting, even by a relatively dim 100 to 200 lux when pupils are dilated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/41,53,54\">",
"     41,53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     High dose melatonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first person to examine the physiological or behavioral effects of exogenous melatonin was the person who discovered it, Aaron Lerner, who reported giving himself 200 mg intravenously per day for five consecutive days [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/55\">",
"     55",
"    </a>",
"    ]. He described feeling \"relaxed.\" Neither Lerner nor the investigators who subsequently gave it (in doses of 10 mg to 6.6 g) to 96 other subjects prior to 1977 measured its effects on plasma melatonin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/55\">",
"     55",
"    </a>",
"    ]. However, since most gave doses in excess of 1 g, it can be assumed that the increases in plasma melatonin were massive. When one trial administered 80 mg doses to two male volunteers in 1987, plasma concentrations increased by more than 1000-fold and serum prolactin levels rose significantly [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/56\">",
"     56",
"    </a>",
"    ], an effect not observed with more physiologic melatonin doses.",
"   </p>",
"   <p>",
"    In 1993, one study examined the effects of 10, 20, 40, or 80 mg melatonin on various behavioral indices (auditory vigilance; self-reported fatigue, confusion, and sleepiness; reaction times), body temperature, and plasma melatonin concentrations. All of the doses tested produced similar and significant changes in the behavioral assays, reduced body temperature, and raised plasma melatonin concentrations to at least 5000",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    well beyond the normal nocturnal range of 100 to 200",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Physiologic dose melatonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The study described above [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/57\">",
"     57",
"    </a>",
"    ] was repeated using much lower doses (0.1 to 10 mg orally) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/58\">",
"     58",
"    </a>",
"    ]. They found that oral doses as low as 0.1 to 0.3 mg caused dose-related decreases in sleep latency and increases in sleep duration and self-reported sleepiness and fatigue, but without reducing body temperature or elevating plasma melatonin concentrations beyond their normal nocturnal range (",
"    <a class=\"graphic graphic_figure graphicRef64467 \" href=\"UTD.htm?24/4/24654\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/58\">",
"     58",
"    </a>",
"    ]. This suggested that nocturnal melatonin secretion, which produces plasma melatonin concentrations similar to those seen after the 0.3 mg dose, does have a physiologic effect on sleep. It also identified the dose range that clinicians and investigators need to use if they want to examine melatonin's physiologic effects.",
"   </p>",
"   <p>",
"    We currently suggest physiologic dose melatonin for the management of age-related insomnia (problems with sleep efficiency). (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Sleep'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Melatonin bioavailability",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is considerable person-to-person variability in the bioavailability of melatonin. In one study using single 80 mg doses, there were 25-fold variations in AUCs (areas under the curve) for the five subjects studied [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/59\">",
"     59",
"    </a>",
"    ]. In another, using 0.5 mg oral doses, peak plasma melatonin concentrations among the four subjects varied from 480 to 9200",
"    <span class=\"nowrap\">",
"     ng/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/60\">",
"     60",
"    </a>",
"    ]. Melatonin's bioavailability was relatively poor, 10 to 56 percent, which the authors attributed to person-to-person differences in first-pass hepatic extraction. Perhaps reflecting such differences in hepatic function, older subjects in another study given a 0.3 mg oral dose of melatonin were found to exhibit considerably greater increments in plasma melatonin concentrations, with correspondingly greater variability, than young adults receiving that dose [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings all suggest that, while a 0.3 mg dose given to young subjects during the daytime or to older insomniacs at night can on average produce normal nocturnal plasma melatonin concentrations, some individuals may need slightly more or significantly less melatonin to attain this effect.",
"   </p>",
"   <p>",
"    The pharmacokinetic properties of any oral dose of melatonin can also vary widely based upon the lipid-solubility of the inert ingredients that accompany it. A preparation containing corn oil plus 0.05 mg melatonin elevated plasma melatonin concentrations to as high a peak (from 4 to 118",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/62\">",
"     62",
"    </a>",
"    ], though for a shorter period, as one containing 0.3 mg melatonin plus microcrystalline cellulose (15 to 105",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CLINICAL EFFECTS OF EXOGENOUS MELATONIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because melatonin is available as a dietary supplement and is relatively nontoxic, clinicians, researchers, and even consumers are able to administer or consume doses that elevate its plasma concentrations to hundreds or even thousands of times those that occur normally [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/56,63\">",
"     56,63",
"    </a>",
"    ]. Even the 1 to 10 mg doses most commonly marketed raise plasma concentrations to 3 to 60 times their normal peak values [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not surprisingly, such supraphysiologic concentrations of melatonin produce numerous biological effects, including daytime sleepiness, impaired mental and physical performance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/64\">",
"     64",
"    </a>",
"    ], hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/62\">",
"     62",
"    </a>",
"    ], and hyperprolactinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/56\">",
"     56",
"    </a>",
"    ]. However, the demonstration that pharmacologic doses of melatonin produce a given biological effect in no way implies that this effect also occurs normally at nighttime plasma melatonin concentrations, nor that the age-related decline in plasma melatonin concentrations results in opposite effects. As an example, melatonin concentrations hundreds or thousands times normal can inhibit the aggregation of A-beta peptides to form amyloid in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/65\">",
"     65",
"    </a>",
"    ]. However, the normal nocturnal rise in plasma melatonin has no demonstrable effects on APP metabolism and there is no evidence whatsoever that the age-related decline in plasma melatonin is an independent risk factor for Alzheimer disease.",
"   </p>",
"   <p>",
"    Exogenous melatonin administration appears to have two effects like those occurring physiologically with nocturnal melatonin secretion: the promotion of sleep onset and maintenance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/25-27,58,66-82\">",
"     25-27,58,66-82",
"    </a>",
"    ], and the phase-shifting of circadian rhythms, including the rhythm in melatonin itself [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/83\">",
"     83",
"    </a>",
"    ]. Both have been shown to be produced by physiologic doses (ie, 0.1 to 0.3 mg for sleep and 0.3 to 0.5 mg for phase-shifting, doses which raise daytime plasma melatonin levels into the normal nocturnal range observed in young adults).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Sleep",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melatonin can directly affect parameters of sleep itself, decreasing sleep latency, increasing sleep efficiency, and increasing total sleep time. We currently suggest physiologic dose melatonin for individuals with age-related insomnia (problems with sleep efficiency). The hormone can also affect sleep indirectly, acting via the mechanisms that control circadian rhythms to change the phasing of the sleep rhythm.",
"   </p>",
"   <p>",
"    For most adults, we suggest a starting melatonin dose of 0.3 mg (or 0.2 mg in patients weighing less than 120",
"    <span class=\"nowrap\">",
"     lbs/54.5",
"    </span>",
"    kg), taken at or soon before bedtime. If after a week nocturnal awakenings have not become less frequent and the time required for falling back asleep has not decreased, we usually double the bedtime dose or suggest that the patient take a second 0.3 mg dose if still awake, nocturnally, after 10 to 15 minutes. If the patient initially responds to the melatonin but stops responding well after a few weeks, we suggest taking a \"drug holiday\" and then restarting the melatonin at the initial dose.",
"   </p>",
"   <p>",
"    A 1997 review of melatonin and sleep included 24 studies, almost all of which described sedation, fatigue, decreased alertness, increased reaction time, shortened sleep latency (ie, number of minutes needed to fall asleep), increased sleep efficiency (ie, percent of the total sleep period actually spent sleeping),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased total sleep time.",
"   </p>",
"   <p>",
"    A meta-analysis published in 2005 included 17 studies involving 284 subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/25\">",
"     25",
"    </a>",
"    ]. In this meta-analysis, melatonin administration was found to cause:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant decrease in sleep latency (by four minutes; 95% CI 2.5-5.4)",
"     </li>",
"     <li>",
"      A significant increase in sleep efficiency (2.2 percent, 95% CI 0.2-4.2)",
"     </li>",
"     <li>",
"      A significant increase in total sleep duration (12.8 minutes; 95% CI 2.9-22.8)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 17 studies included in this meta-analysis were far more heterogeneous than those in meta-analyses of drugs already approved for treating specific indications at specific doses, reflecting melatonin's anomalous status as an unregulated dietary supplement. Subjects received doses ranging from 0.1 mg to 80 mg for one day to two months, and included those who slept normally, or suffered from insomnia caused by age-related impairments in sleep efficiency or by time-zone shifts, or was secondary to Alzheimer disease or schizophrenia. Since, as an example, age-related insomnia has little effect on sleep latency while the insomnia of \"jet lag\" principally affects this parameter, it's almost surprising that significant results were obtained. Melatonin would not be expected to decrease sleep latency among older subjects, in whom latency was already normal, nor to increase sleep efficiency among time-zone-shifted younger people who had little difficulty sleeping through the night.",
"   </p>",
"   <p>",
"    Two additional meta-analyses have confirmed that oral melatonin significantly reduces sleep latency in normal individuals and those with insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. A third meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/84\">",
"     84",
"    </a>",
"    ], which included only studies involving patients with secondary insomnia (related to an underlying neurologic or psychiatric disease) or with insomnia resulting from sleep restriction (such as jet lag and shiftwork), concluded that melatonin is ineffective in these particular disorders. However, almost all of the studies cited used very high melatonin doses which were probably sufficient to desensitize melatonin's receptors. Moreover, this meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/84\">",
"     84",
"    </a>",
"    ] did demonstrate a statistically significant improvement in sleep efficiency, even though it excluded the patients (those with age-related insomnia) in whom decreased sleep efficiency most often tends to be a problem. The improvement was comparable (1.9 percent) to that produced by ramelteon (2.5 percent), a hypnotic melatonin analog [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/21,85\">",
"     21,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Experimental paradigms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of exogenous melatonin on sleep have been examined under three types of experimental conditions in relation to the onset or offset of endogenous melatonin secretion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some studies, the hormone was administered during the daily light period, such that blood melatonin concentrations would be transiently elevated, but would then return to baseline before the initiation of nocturnal melatonin secretion. Such experiments were used to demonstrate that melatonin can decrease sleep latency when given at any time in the afternoon or evening; hence, this effect is independent of the hormone's action on the mechanisms that generate circadian rhythms (since no treatment can immediately shift the phase of a circadian rhythm by 8 to 10 hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In others, the hormone was also given during the light period, but close enough to the onset of darkness so that melatonin concentrations would still be elevated when nocturnal melatonin secretion started [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/75,77\">",
"       75,77",
"      </a>",
"      ]. The period during which plasma melatonin concentrations were continuously elevated would thus be prolonged. Such experiments modeled the use of melatonin to decrease sleep latency and maintain continuous sleep, as an example, among shift-workers or in eastbound world travelers who had to start going to bed earlier.",
"     </li>",
"     <li>",
"      In a third paradigm, the hormone was given at the end of the light period to older insomniacs with low nighttime plasma melatonin concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/80\">",
"       80",
"      </a>",
"      ]. The intent was to prolong the portion of the night during which plasma melatonin concentrations would be elevated to the same range as those of non-insomniac young adults.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all of these situations, exogenous melatonin decreased sleep latency when it was elevated and, when tested, increased sleep duration and sleep efficiency. A 0.3 mg dose was either as effective as, or more effective than, higher doses [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/75,77,80\">",
"     75,77,80",
"    </a>",
"    ], particularly when the hormone was administered for several days. Unlike the higher doses, this low dose had no effect on body temperature, affirming that, while pharmacologic doses can cause hypothermia, melatonin's ability to promote sleep is not mediated by such a change, as had been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Sleep architecture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hormone had no consistent effect on sleep architecture, neither increasing nor decreasing the portion of the sleep period during which subjects exhibited REM. Its effects were different from those usually associated with hypnotic drugs, since after melatonin, subjects could readily keep from falling asleep if they so chose, and their cognitive abilities the morning after receiving the hormone were unchanged or improved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/75,77\">",
"     75,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Insomnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study using 30 subjects who were 50 years old or older with or without clinically-significant insomnia (ie, sleep efficiencies of 70 to 80 percent in the insomniacs versus 92 percent in controls) and who received each of four randomized doses of melatonin (0, 0.1, 0.3, or 3.0 mg) orally for a week, with one-week washout periods, the following results were seen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/80\">",
"     80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Melatonin produced significant improvements in sleep efficiency (particularly during the middle portion of the nocturnal sleep period) (",
"      <a class=\"graphic graphic_figure graphicRef58496 \" href=\"UTD.htm?2/51/2878\">",
"       figure 4",
"      </a>",
"      ) in patients with insomnia. The 0.3 mg dose produced the greatest effect (",
"      <a class=\"graphic graphic_figure graphicRef79057 \" href=\"UTD.htm?24/6/24686\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with insomnia, no effects were seen in total sleep time, latency to sleep onset (not abnormal in this population), REM sleep, or percent time spent in any of the sleep stages. However, no improvement would be expected in sleep latency in these patients as their problem was with waking up during the night (sleep efficiency), not with falling asleep (sleep latency).",
"     </li>",
"     <li>",
"      In patients without insomnia, no effects on any sleep parameters were seen.",
"     </li>",
"     <li>",
"      Dose-related increases in plasma melatonin concentrations were observed. The 0.3 mg dose resulted in peak concentrations in the normal nocturnal young adult range.",
"     </li>",
"     <li>",
"      10 hours after administration of the 0.1 and 0.3 mg doses, plasma melatonin concentrations were no different than those for placebo. However, in the 3 mg group, melatonin concentrations remained significantly elevated for much of the following day (",
"      <a class=\"graphic graphic_figure graphicRef53725 \" href=\"UTD.htm?18/8/18574\">",
"       figure 6",
"      </a>",
"      ). The 3 mg dose (but not the 0.1 or 0.3 mg doses) also resulted in hypothermia (",
"      <a class=\"graphic graphic_figure graphicRef67860 \" href=\"UTD.htm?38/21/39262\">",
"       figure 7",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effects of melatonin agonists for insomnia are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link\">",
"     \"Treatment of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Melatonin agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;A synthetic melatonin agonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15125?source=see_link\">",
"     ramelteon",
"    </a>",
"    , thought to activate MT1 and MT2 melatonin receptors selectively, is available in the United States (as a non-scheduled drug) for the treatment of chronic insomnia, but not in the European Union, where it was denied approval. No data are available that directly compare the efficacies and toxicities of this compound with those of the much lower recommended dose (0.3 mg) of melatonin. The use of melatonin agonists for the treatment of insomnia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of insomnia\", section on 'Melatonin agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second melatonin agonist, tasimelteon (VEC-162) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/22\">",
"     22",
"    </a>",
"    ], may be a promising option for improving sleep latency and sleep maintenance in individuals with jet lag disorder or in those who have sleep problems due to starting work at very early hours. It appears to reduce sleep onset latency and to reset the circadian plasma melatonin rhythm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=see_link&amp;anchor=H11#H11\">",
"     \"Jet lag\", section on 'Melatonin agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Circadian rhythms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Phase-shifting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of exogenous melatonin to synchronize and to shift the phases of various human circadian rhythms is generally accepted. In studies of healthy volunteers, 0.5 mg of pure melatonin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/83\">",
"     83",
"    </a>",
"    ] or 0.05 mg of melatonin in corn oil (which causes earlier peaks in, and the more rapid disappearance of, elevated plasma melatonin concentrations) was able to advance the onset of nocturnal melatonin secretion when administered at 5 pm, and larger doses caused greater phase advances [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, melatonin was able to shift the core body temperature rhythm; however, a statistically significant effect was found only with doses &ge;0.5 mg. These doses increased plasma melatonin concentrations well above the upper limits of normal (&gt;1327",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As described above, melatonin can also control the timing of the sleep and sleepiness rhythms, an effect readily demonstrated among blind individuals with free-running melatonin and sleep rhythms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/86\">",
"     86",
"    </a>",
"    ], but also among sighted individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/71,87\">",
"     71,87",
"    </a>",
"    ]. Moreover, physiologic doses (0.3 mg) entrain a variety of otherwise free-running rhythms in blind individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Jet lag",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melatonin's ability to phase-shift circadian rhythms underlies its common use to prevent or treat \"jet lag,\" particularly that associated with eastbound travel [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/89\">",
"     89",
"    </a>",
"    ]. The role of melatonin therapy for prevention of jet lag is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=see_link&amp;anchor=H6#H6\">",
"     \"Jet lag\", section on 'Exogenous melatonin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Antioxidant",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that melatonin is a potent antioxidant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/90,91\">",
"     90,91",
"    </a>",
"    ], and that melatonin supplements may protect against such age-related diseases as atherosclerosis, cancer, and Alzheimer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/65,92-96\">",
"     65,92-96",
"    </a>",
"    ]. None of these proposed uses has been tested in a controlled clinical trial nor has any been approved for use. Most studies have not provided plasma melatonin data and most have not compared melatonin's effects to those of known antioxidants [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has usually been possible to demonstrate antioxidant or free radical scavenger effects of melatonin in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/63,90\">",
"     63,90",
"    </a>",
"    ], however, such studies generally have required melatonin concentrations 1000 to 100,000 times those ever occurring in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/63\">",
"     63",
"    </a>",
"    ]. Similarly, while high doses of melatonin (10 to 450",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight parenterally) have sometimes elicited antioxidant effects in experimental animals in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/99\">",
"     99",
"    </a>",
"    ], neither their long-term safety nor their effects on the animals' melatonin concentrations have been characterized. In humans, such megadoses might ultimately impair sleep or various circadian rhythms, perhaps by desensitizing melatonin receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only one study has described careful dose-response experiments on the ability of melatonin to protect against auto-oxidation, and has compared melatonin with known antioxidants [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/63\">",
"     63",
"    </a>",
"    ]. That study examined the cell-mediated (by human macrophages) and cell-free (by copper sulfate) oxidation of low density lipoproteins (LDL), a process believed to contribute to atherosclerosis. Melatonin did exhibit weak antioxidant activity, but only at 10,000- to 100,000-fold physiologic concentrations. In contrast, a vitamin E preparation (alpha-tocopherol) was 50- to 100-fold more potent than melatonin, and was effective at physiologic concentrations. Similarly, vitamin C (ascorbic acid) and tryptophan, melatonin's indolic circulating precursor, were significantly more potent than melatonin, and were active at physiologic concentrations. Thus, melatonin appears to have, at best, very weak antioxidant activity, but only at extremely supraphysiologic concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, plasma melatonin concentrations decline with age. In patients with dementia, melatonin levels may decline to an even greater extent than in normal aging. However, melatonin does not appear to have a beneficial effect on cognition in patients with dementia. The effect of melatonin on noncognitive symptoms such as sleep and agitation is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of behavioral symptoms related to dementia\", section on 'Other agents and approaches'",
"    </a>",
"    .) One paper suggests that if demented patients are to be treated with melatonin, they should also be exposed to supplemental light to block any adverse effects on mood [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Other effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Nocturnal blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;While sleeping at night, the blood pressure normally falls by approximately 15 percent from daytime values. Patients in whom this reduction does not occur are considered to have nocturnal hypertension, which has been associated with an excess risk of cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link&amp;anchor=H10#H10\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'Nocturnal blood pressure and nondippers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two observations suggest the melatonin plays a role in nocturnal blood pressure regulation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal nighttime surge in serum melatonin concentration may be blunted in patients with nocturnal hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/101\">",
"       101",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Melatonin administration appears to lower blood pressure, particularly at night [",
"      <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/102-105\">",
"       102-105",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a randomized trial, 38 men with treated hypertension and confirmed nocturnal hypertension (mean nighttime systolic BP &gt;125 mmHg) were assigned to receive controlled-release melatonin (2 mg) or placebo two hours before bedtime for four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/105\">",
"     105",
"    </a>",
"    ]. Significant reductions in nocturnal systolic and diastolic blood pressures (mean",
"    <span class=\"nowrap\">",
"     6/3",
"    </span>",
"    mmHg) were observed in the melatonin, but not the placebo group. The effect on blood pressure could not be explained by a change in sleep quality.",
"   </p>",
"   <p>",
"    A significant fall in nocturnal blood pressure was also noted in a smaller randomized trial in which melatonin had no effect on daytime blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, exogenous melatonin may have a modest effect on nocturnal blood pressure. However, we do not currently recommend its use for this indication since there are no data showing improved outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Antiaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some investigators suggest, based on small studies in laboratory rodents, that melatonin \"maintains juvenile conditions\" and is a \"geroprotector\" [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. There is no evidence that melatonin has any \"antiaging\" effects in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the fact that melatonin is an unregulated drug in many countries and is often used in excessive doses, there does not appear to be a major pattern of side effects. One report described a search for reports of adverse effects with melatonin over 35 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/46/13034/abstract/108\">",
"     108",
"    </a>",
"    ]. In those that described adverse effects, pharmacologic doses had been used (1 to 36 mg).",
"   </p>",
"   <p>",
"    In the absence of governmental regulation, companies are able to sell melatonin at doses that are many times those needed for promoting sleep or shifting rhythms, or for restoring normal nocturnal plasma melatonin levels in older people. These doses can elevate plasma melatonin to levels thousands of times greater than ever occur normally, and produce mild but not benign side-effects, like hypothermia and \"hangovers.\" Paradoxically, they also may, through receptor desensitization, exacerbate the insomnia that the consumer was trying to treat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19602?source=see_link\">",
"       \"Patient information: Jet lag (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melatonin is synthesized at nighttime in the human pineal gland, and released into the blood and the cerebrospinal fluid. It acts on the brains of humans and other diurnally-active mammals to promote sleep, and also influences the phasing of sleep and various other circadian rhythms. During the daytime, plasma melatonin concentrations are low; at nighttime, they rise by 10- to 30-fold or more in young adults, but by considerably less in older people, who may have frequent nocturnal awakenings as a consequence.",
"   </p>",
"   <p>",
"    Recommendations for the clinical use of exogenous melatonin are presented here:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Sleep",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For individuals with age-related insomnia (problems with sleep efficiency), we suggest melatonin therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      For most adults, we suggest a starting melatonin dose of 0.3 mg (or 0.2 mg in patients weighing less than 120",
"      <span class=\"nowrap\">",
"       lbs/54.5",
"      </span>",
"      kg), taken at or soon before bedtime (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If after a week nocturnal awakenings have not become less frequent and the time required for falling back asleep has not decreased, we usually double the bedtime dose or suggest that the patient take a second 0.3 mg dose if still awake, nocturnally, after 10 to 15 minutes. If the patient initially responds to the melatonin but stops responding well after a few weeks, we suggest taking a \"drug holiday\" and then restarting the melatonin at the initial dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Jet lag",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Jet lag recommendations are found separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=see_link\">",
"       \"Jet lag\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Cognitive impairment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with cognitive impairment associated with dementia, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      using melatonin treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Dementia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of reports of adverse events possibly related to melatonin in patients with seizure disorders or in those taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or other oral anticoagulants, we suggest not using melatonin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In the absence of safety and efficacy data in children, we suggest not using melatonin&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/1\">",
"      McCord, CP, Allen, FP. Evidences associating pineal gland function of alterations in pigmentation. J Exptl Zool 1917; 23:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/2\">",
"      Lerner, AB, Case, JD, Takahashi, Y, Lee, TH, Mori, W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc 1958; 80:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/3\">",
"      Kitay, JI, Altschule, MD. Effects of pineal extract administration on ovary weight in rats. Endocrinol 1954; 55:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/4\">",
"      Fiske, VM, Bryant, K, Putnam, J. Effect of light on the weight of pineal in the rat. J Endocrinol 1960; 66:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/5\">",
"      Ariens-Kappers, J. Innervation of the Epiphysis cerebri in the albino rat. Anat Rec 1960; 136:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/6\">",
"      WURTMAN RJ, ROTH W, ALTSCHULE MD, WURTMAN JJ. Interactions of the pineal and exposure to continuous light on organ weights of female rats. Acta Endocrinol (Copenh) 1961; 36:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/7\">",
"      WURTMAN RJ, AXELROD J, CHU EW. Melatonin, a pineal substance: effect on the rat ovary. Science 1963; 141:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/8\">",
"      WURTMAN RJ, AXELROD J, PHILLIPS LS. MELATONIN SYNTHESIS IN THE PINEAL GLAND: CONTROL BY LIGHT. Science 1963; 142:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/9\">",
"      WURTMAN RJ, AXELROD J, FISCHER JE. MELATONIN SYNTHESIS IN THE PINEAL GLAND: EFFECT OF LIGHT MEDIATED BY THE SYMPATHETIC NERVOUS SYSTEM. Science 1964; 143:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/10\">",
"      Axelrod J, Shein HM, Wurtman RJ. Stimulation of C14-melatonin synthesis from C14-tryptophan by noradrenaline in rat pineal in organ culture. Proc Natl Acad Sci U S A 1969; 62:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/11\">",
"      Wurtman RJ, Shein HM, Larin F. Mediation by -adrenergic receptors of effect of norepinephrine on pineal synthesis of ( 14 C)serotonin and ( 14 C)melatonin. J Neurochem 1971; 18:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/12\">",
"      Shein HM, Wurtman RJ. Cyclic adenosine monophosphate: stimulation of melatonin and serotonin synthesis in cultured rat pineals. Science 1969; 166:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/13\">",
"      QUAY WB. CIRCADIAN RHYTHM IN RAT PINEAL SEROTONIN AND ITS MODIFICATIONS BY ESTROUS CYCLE AND PHOTOPERIOD. Gen Comp Endocrinol 1963; 14:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/14\">",
"      Lynch HJ. Diurnal oscillations in pineal melatonin content. Life Sci I 1971; 10:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/15\">",
"      Moore RY, Klein DC. Visual pathways and the central neural control of a circadian rhythm in pineal serotonin N-acetyltransferase activity. Brain Res 1974; 71:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/16\">",
"      Lynch HJ, Wurtman RJ, Moskowitz MA, et al. Daily rhythm in human urinary melatonin. Science 1975; 187:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/17\">",
"      Lynch HJ, Jimerson DC, Ozaki Y, et al. Entrainment of rhythmic melatonin secretion in man to a 12-hour phase shift in the light/dark cycle. Life Sci 1978; 23:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/18\">",
"      WURTMAN RJ, AXELROD J. THE PINEAL GLAND. Sci Am 1965; 213:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/19\">",
"      Waldhauser F, Weiszenbacher G, Frisch H, et al. Fall in nocturnal serum melatonin during prepuberty and pubescence. Lancet 1984; 1:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/20\">",
"      Srinivasan V, Spence WD, Pandi-Perumal SR, et al. Melatonin and human reproduction: Shedding light on the darkness hormone. Gynecol Endocrinol 2009; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/21\">",
"      Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006; 7:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/22\">",
"      Hardeland R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. Curr Opin Investig Drugs 2009; 10:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/23\">",
"      Jansen SL, Forbes DA, Duncan V, Morgan DG. Melatonin for cognitive impairment. Cochrane Database Syst Rev 2006; :CD003802.",
"     </a>",
"    </li>",
"    <li>",
"     European Food Safety Authority. Scientific opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to article 13(1) of regulation (EC) No 1924/2006. EFSA Journal 2011; 9:2241. file://www.efsa.europa.eu/en/efsajournal/doc/2241.pdf (Accessed on September 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/25\">",
"      Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9:41.",
"     </a>",
"    </li>",
"    <li>",
"     Buscemi N, Vandermeer B, Pandya R, et al. Melatonin for treatment of sleep disorders. Summary, evidence report/technology assessment: Number 108. AHRQ Publication Number 05-E002-1, November 2004. Agency for Healthcare Research and Quality, Rockville, MD. file://www.ahrq.gov/clinic/epcsums/melatsum.htm (Accessed on September 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/27\">",
"      Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 2005; 20:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/28\">",
"      Ozaki Y, Lynch HJ. Presence of melatonin in plasma and urine or pinealectomized rats. Endocrinology 1976; 99:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/29\">",
"      Neuwelt EA, Lewy AJ. Disappearance of plasma melatonin after removal of a neoplastic pineal gland. N Engl J Med 1983; 308:1132.",
"     </a>",
"    </li>",
"    <li>",
"     Klein DC. The pineal gland: A model of neuroendocrine regulation. In: The Hypothalamus, Reichlin S, Baldessarini RJ, Martin JB (Eds), Raven Press, New York 1978. p.303.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/31\">",
"      AXELROD J, WEISSBACH H. Enzymatic O-methylation of N-acetylserotonin to melatonin. Science 1960; 131:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/32\">",
"      Skene DJ, Vivien-Roels B, Sparks DL, et al. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease. Brain Res 1990; 528:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/33\">",
"      Tricoire H, Locatelli A, Chemineau P, Malpaux B. Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology 2002; 143:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/34\">",
"      WURTMAN RJ, AXELROD J, POTTER LT. THE UPTAKE OF H3-MELATONIN IN ENDOCRINE AND NERVOUS TISSUES AND THE EFFECTS OF CONSTANT LIGHT EXPOSURE. J Pharmacol Exp Ther 1964; 143:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/35\">",
"      Cardinali DP, Lynch HJ, Wurtman RJ. Binding of melatonin to human and rat plasma proteins. Endocrinology 1972; 91:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/36\">",
"      KOPIN IJ, PARE CM, AXELROD J, WEISSBACH H. 6-Hydroxylation, the major metabolic pathway for melatonin. Biochim Biophys Acta 1960; 40:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/37\">",
"      Witt-Enderby PA, Bennett J, Jarzynka MJ, et al. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci 2003; 72:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/38\">",
"      Wang LM, Suthana NA, Chaudhury D, et al. Melatonin inhibits hippocampal long-term potentiation. Eur J Neurosci 2005; 22:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/39\">",
"      Gerdin MJ, Masana MI, Rivera-Berm&uacute;dez MA, et al. Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB J 2004; 18:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/40\">",
"      Gerdin MJ, Masana MI, Dubocovich ML. Melatonin-mediated regulation of human MT(1) melatonin receptors expressed in mammalian cells. Biochem Pharmacol 2004; 67:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/41\">",
"      Lewy AJ, Wehr TA, Goodwin FK, et al. Light suppresses melatonin secretion in humans. Science 1980; 210:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/42\">",
"      Klein DC, Moore RY. Pineal N-acetyltransferase and hydroxyindole-O-methyltransferase: control by the retinohypothalamic tract and the suprachiasmatic nucleus. Brain Res 1979; 174:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/43\">",
"      Dubbels R, Reiter RJ, Klenke E, et al. Melatonin in edible plants identified by radioimmunoassay and by high performance liquid chromatography-mass spectrometry. J Pineal Res 1995; 18:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/44\">",
"      Hattori A, Migitaka H, Iigo M, et al. Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. Biochem Mol Biol Int 1995; 35:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/45\">",
"      Van Tassel DL, Roberts N, Lewy A, O'Neill SD. Melatonin in plant organs. J Pineal Res 2001; 31:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/46\">",
"      Kennaway DJ, Stamp GE, Goble FC. Development of melatonin production in infants and the impact of prematurity. J Clin Endocrinol Metab 1992; 75:367.",
"     </a>",
"    </li>",
"    <li>",
"     Waldhauser F, Lynch HJ, Wurtman RJ. Melatonin in human body fluids: Clinical significance. In: The Pineal Gland (Comprehensive Endocrinology), Reiter RJ (Ed), Raven Press, New York 1984. p.345.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/48\">",
"      Mayeda A, Mannon S, Hofstetter J, et al. Effects of indirect light and propranolol on melatonin levels in normal human subjects. Psychiatry Res 1998; 81:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/49\">",
"      Garde E, Micic S, Knudsen K, et al. 8-methoxypsoralen increases daytime plasma melatonin levels in humans through inhibition of metabolism. Photochem Photobiol 1994; 60:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/50\">",
"      Wright KP Jr, Badia P, Myers BL, et al. Caffeine and light effects on nighttime melatonin and temperature levels in sleep-deprived humans. Brain Res 1997; 747:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/51\">",
"      R&ouml;jdmark S, Wikner J, Adner N, et al. Inhibition of melatonin secretion by ethanol in man. Metabolism 1993; 42:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/52\">",
"      Ekman AC, Lepp&auml;luoto J, Huttunen P, et al. Ethanol inhibits melatonin secretion in healthy volunteers in a dose-dependent randomized double blind cross-over study. J Clin Endocrinol Metab 1993; 77:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/53\">",
"      Brainard GC, Rollag MD, Hanifin JP. Photic regulation of melatonin in humans: ocular and neural signal transduction. J Biol Rhythms 1997; 12:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/54\">",
"      Aoki H, Yamada N, Ozeki Y, et al. Minimum light intensity required to suppress nocturnal melatonin concentration in human saliva. Neurosci Lett 1998; 252:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/55\">",
"      Lerner AB, Nordlund JJ. Melatonin: clinical pharmacology. J Neural Transm Suppl 1978; :339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/56\">",
"      Waldhauser F, Lieberman HR, Lynch HJ, et al. A pharmacological dose of melatonin increases PRL levels in males without altering those of GH, LH, FSH, TSH, testosterone or cortisol. Neuroendocrinology 1987; 46:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/57\">",
"      Dollins AB, Lynch HJ, Wurtman RJ, et al. Effect of pharmacological daytime doses of melatonin on human mood and performance. Psychopharmacology (Berl) 1993; 112:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/58\">",
"      Dollins AB, Zhdanova IV, Wurtman RJ, et al. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci U S A 1994; 91:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/59\">",
"      Waldhauser F, Waldhauser M, Lieberman HR, et al. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984; 39:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/60\">",
"      Di WL, Kadva A, Johnston A, Silman R. Variable bioavailability of oral melatonin. N Engl J Med 1997; 336:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/61\">",
"      Zhdanova, I, Wurtman, RJ, Balcioglu, A, Kartashov, AI, et al. Endogenous melatonin levels and the fate of exogenous melatonin: Age effects. J Gerontology 1998; 53:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/62\">",
"      Deacon S, Arendt J. Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans. Brain Res 1995; 688:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/63\">",
"      Duell PB, Wheaton DL, Shultz A, Nguyen H. Inhibition of LDL oxidation by melatonin requires supraphysiologic concentrations. Clin Chem 1998; 44:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/64\">",
"      Atkinson G, Jones H, Edwards BJ, Waterhouse JM. Effects of daytime ingestion of melatonin on short-term athletic performance. Ergonomics 2005; 48:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/65\">",
"      Pappolla M, Bozner P, Soto C, et al. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem 1998; 273:7185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/66\">",
"      Zhdanova IV, Wurtman RJ. Efficacy of melatonin as a sleep-promoting agent. J Biol Rhythms 1997; 12:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/67\">",
"      Cramer H, Rudolph J, Consbruch U, Kendel K. On the effects of melatonin on sleep and behavior in man. Adv Biochem Psychopharmacol 1974; 11:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/68\">",
"      James SP, Mendelson WB, Sack DA, et al. The effect of melatonin on normal sleep. Neuropsychopharmacology 1987; 1:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/69\">",
"      James SP, Sack DA, Rosenthal NE, Mendelson WB. Melatonin administration in insomnia. Neuropsychopharmacology 1990; 3:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/70\">",
"      Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology (Berl) 1990; 100:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/71\">",
"      Dahlitz M, Alvarez B, Vignau J, et al. Delayed sleep phase syndrome response to melatonin. Lancet 1991; 337:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/72\">",
"      Haimov I, Lavie P, Laudon M, et al. Melatonin replacement therapy of elderly insomniacs. Sleep 1995; 18:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/73\">",
"      Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995; 346:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/74\">",
"      Wurtman RJ, Zhdanova I. Improvement of sleep quality by melatonin. Lancet 1995; 346:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/75\">",
"      Zhdanova IV, Wurtman RJ, Lynch HJ, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther 1995; 57:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/76\">",
"      Attenburrow ME, Cowen PJ, Sharpley AL. Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology (Berl) 1996; 126:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/77\">",
"      Zhdanova IV, Wurtman RJ, Morabito C, et al. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep 1996; 19:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/78\">",
"      Hughes RJ, Badia P. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep 1997; 20:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/79\">",
"      Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep 1998; 21:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/80\">",
"      Zhdanova IV, Wurtman RJ, Regan MM, et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001; 86:4727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/81\">",
"      Shamir E, Laudon M, Barak Y, et al. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatry 2000; 61:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/82\">",
"      Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003; 26:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/83\">",
"      Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992; 9:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/84\">",
"      Buscemi N, Vandermeer B, Hooton N, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006; 332:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/85\">",
"      Ferguson SA, Rajaratnam SM, Dawson D. Melatonin agonists and insomnia. Expert Rev Neurother 2010; 10:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/86\">",
"      Sack RL, Lewy AJ, Blood ML, et al. Melatonin administration to blind people: phase advances and entrainment. J Biol Rhythms 1991; 6:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/87\">",
"      Middleton B, Arendt J, Stone BM. Complex effects of melatonin on human circadian rhythms in constant dim light. J Biol Rhythms 1997; 12:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/88\">",
"      Lewy AJ, Emens JS, Lefler BJ, et al. Melatonin entrains free-running blind people according to a physiological dose-response curve. Chronobiol Int 2005; 22:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/89\">",
"      Arendt J. Jet-lag and shift work: (2). Therapeutic use of melatonin. J R Soc Med 1999; 92:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/90\">",
"      Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 1998; 56:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/91\">",
"      Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/92\">",
"      Pierpaoli W, Yi CX, Dall'Ara A. Aging-postponing effects of circadian melatonin: experimental evidence, significance and possible mechanisms. Int J Neurosci 1990; 51:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/93\">",
"      Poeggeler B, Reiter RJ, Tan DX, et al. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. J Pineal Res 1993; 14:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/94\">",
"      Grad BR, Rozencwaig R. The role of melatonin and serotonin in aging: update. Psychoneuroendocrinology 1993; 18:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/95\">",
"      Chen ST, Chuang JI. The antioxidant melatonin reduces cortical neuronal death after intrastriatal injection of kainate in the rat. Exp Brain Res 1999; 124:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/96\">",
"      Pappolla MA, Chyan YJ, Poeggeler B, et al. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J Neural Transm 2000; 107:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/97\">",
"      Bonn, D. Melatonin's multifarious marvels: Miracle or myth? Lancet 1996; 347:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/98\">",
"      Brzezinski A. Melatonin in humans. N Engl J Med 1997; 336:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/99\">",
"      Reiter RJ, Tan DX, Poeggeler B, et al. Melatonin as a free radical scavenger: implications for aging and age-related diseases. Ann N Y Acad Sci 1994; 719:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/100\">",
"      Riemersma-van der Lek RF, Swaab DF, Twisk J, et al. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA 2008; 299:2642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/101\">",
"      Jonas M, Garfinkel D, Zisapel N, et al. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press 2003; 12:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/102\">",
"      Arangino S, Cagnacci A, Angiolucci M, et al. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am J Cardiol 1999; 83:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/103\">",
"      Burgess HJ, Sletten T, Savic N, et al. Effects of bright light and melatonin on sleep propensity, temperature, and cardiac activity at night. J Appl Physiol 2001; 91:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/104\">",
"      Cagnacci A, Cannoletta M, Renzi A, et al. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am J Hypertens 2005; 18:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/105\">",
"      Grossman E, Laudon M, Yalcin R, et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med 2006; 119:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/106\">",
"      Pierpaoli W, Bulian D, Dall'Ara A, et al. Circadian melatonin and young-to-old pineal grafting postpone aging and maintain juvenile conditions of reproductive functions in mice and rats. Exp Gerontol 1997; 32:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/107\">",
"      Anisimov VN, Alimova IN, Baturin DA, et al. Dose-dependent effect of melatonin on life span and spontaneous tumor incidence in female SHR mice. Exp Gerontol 2003; 38:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/46/13034/abstract/108\">",
"      Morera AL, Henry M, de La Varga M. [Safety in melatonin use]. Actas Esp Psiquiatr 2001; 29:334.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6634 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-99A7E1262A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13034=[""].join("\n");
var outline_f12_46_13034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Regulatory issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MELATONIN SYNTHESIS AND METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Melatonin receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Circadian rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PLASMA MELATONIN CONCENTRATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Effect of diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effects of drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      High dose melatonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Physiologic dose melatonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Melatonin bioavailability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CLINICAL EFFECTS OF EXOGENOUS MELATONIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Sleep",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Experimental paradigms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Sleep architecture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Insomnia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Melatonin agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Circadian rhythms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Phase-shifting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Jet lag",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Antioxidant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Dementia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Other effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Nocturnal blood pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Antiaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Sleep",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Jet lag",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/6634\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6634|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/7/42110\" title=\"figure 1\">",
"      Metabolism of tryptophan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/23/4478\" title=\"figure 2\">",
"      Nighttime serum melatonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/4/24654\" title=\"figure 3\">",
"      Mean serum melatonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/51/2878\" title=\"figure 4\">",
"      Sleep efficiency insomnia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/6/24686\" title=\"figure 5\">",
"      Sleep efficiency elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/8/18574\" title=\"figure 6\">",
"      Mean group melatonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/21/39262\" title=\"figure 7\">",
"      Melatonin core body temp",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=related_link\">",
"      Jet lag",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19602?source=related_link\">",
"      Patient information: Jet lag (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_46_13035="Causes constipation children";
var content_f12_46_13035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of constipation in infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Most common causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic idiopathic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dietary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Painful defecation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Causes not to miss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infantile botulism (constipation an early complaint, facial and ocular palsies, poor suck and hypotonia are other features)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinal dysraphism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypokalemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hirschsprung's disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tunnessen WJ. Constipation and fecal retention. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p. 518.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13035=[""].join("\n");
var outline_f12_46_13035=null;
var title_f12_46_13036="Severity malnutrition FTT";
var content_f12_46_13036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Systems for assessing the severity of malnutrition in underweight children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Method",
"       </td>",
"       <td class=\"subtitle1\">",
"        Normal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle1\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight for age",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        Percent of median &ge;90 percent",
"       </td>",
"       <td>",
"        Percent of median 75 to 89 percent",
"       </td>",
"       <td>",
"        Percent of median 60 to 74 percent",
"       </td>",
"       <td>",
"        Percent of median &lt;60 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight for height",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        Percent of median &ge;90 percent",
"       </td>",
"       <td>",
"        Percent of median 80 to 89 percent",
"       </td>",
"       <td>",
"        Percent of median 70 to 79 percent",
"       </td>",
"       <td>",
"        Percent of median &lt;70 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Height for age",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        Percent of median &ge;95 percent",
"       </td>",
"       <td>",
"        Percent of median 90 to 94 percent",
"       </td>",
"       <td>",
"        Percent of median 85 to 89 percent",
"       </td>",
"       <td>",
"        Percent of median &lt;85 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight/height for age",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        Percent of median &ge;90 percent",
"       </td>",
"       <td>",
"        Percent of median 85 to 89 percent",
"       </td>",
"       <td>",
"        Percent of median 75 to 84 percent",
"       </td>",
"       <td>",
"        Percent of median &lt;75 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Gomez F. Mortality in third degree malnutrition. J Trop Peds 1956; 2:77.",
"       </li>",
"       <li>",
"        Waterlow JC. Classification and definition of protein-calorie malnutrition. Br Med J 1972; 3:566. This method assesses acute undernutrition.",
"       </li>",
"       <li>",
"        Waterflow JC. Some aspects of childhood malnutrition as a public health problem. Br Med J 1974; 4:88. This method assesses chronic undernutrition.",
"       </li>",
"       <li>",
"        McLaren DS, Read WW. Weight/length classification of nutritional status. Lancet 1975; 2:219.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13036=[""].join("\n");
var outline_f12_46_13036=null;
var title_f12_46_13037="Expansion rates of thoracic aortic aneurysm";
var content_f12_46_13037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Expansion rates of thoracic aortic aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 301px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Segments with initial diameter &ge;60 mm manifested a median expansion rate of 4 mm/year, while smaller aneurysms (&lt;50 mm diameter) had a median expansion rate of 1.33 mm/year (p&lt;0.01).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonser, RS, Pagano, D, Lewis, ME, et al, Heart 2000; 84:277.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13037=[""].join("\n");
var outline_f12_46_13037=null;
var title_f12_46_13038="X linked recessive pedigree";
var content_f12_46_13038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 584px\">",
"   <div class=\"ttl\">",
"    Pedigree of x-linked recessive inheritance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 564px; height: 287px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Females are carriers and only males are affected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Linda Pinsky, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13038=[""].join("\n");
var outline_f12_46_13038=null;
var title_f12_46_13039="Bronchoscopic retrieval";
var content_f12_46_13039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchoscopic retrieval",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    New \"zero tip\" baskets especially dedicated for endobronchial use greatly facilitates extraction of foreign bodies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_46_13039=[""].join("\n");
var outline_f12_46_13039=null;
